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Due to current targeted surveillance programs of healthcare associated infections (HAIs), 
there is a paucity of research on non-device associated urinary tract infections (ND-UTIs), non-
device associated pneumonia (ND-pneumonia), and non-device associated bloodstream 
infections (ND-BSIs). However, limited data that do exist suggest that the proportion of all HAIs 
that were non-device associated have increased over the last decade. Thus, the purpose of this 
study was to update current estimates of ND-HAI rates and their frequency relative to device 
associated infections, assess temporal trends, and identify potential risk factors for ND-HAIs 
among adult patients hospitalized at the University of North Carolina (UNC) Hospitals between 
2013 – 2017.  
Between 2013 and 2017, the rates of ND-UTIs and ND-pneumonia remained relatively 
stable, and the rate of ND-BSIs increased. Additionally, ND-UTIs and ND-pneumonia cases 
represent the majority of infections, with almost 3 in 4 UTIs and pneumonia cases being non-
device associated in 2017. One in three BSIs are non-device associated at UNC Hospitals.  
 Females, older adults, peptic ulcer disease, paralysis, immunosuppression, opioid use, 
TPN, and trauma patients all had a higher risk of ND-UTI. Urinary retention, suprapubic 




were imprecise. Risk factors for ND-pneumonia included male sex, older age, ICU admission, 
and chronic bronchitis/emphysema, congestive heart failure, paralysis, and immunosuppression. 
Finally, risk factors for ND-BSIs included male sex, peptic ulcer disease, paralysis, general 
anesthesia, opioids, and peripheral venous catheters; higher Morse Fall Risk score, beta-blockers, 
and UTIs (device or non-device associated) also appeared to increase patient risk. These results 
all suggest that specific patient and clinical characteristics may increase the risk for certain ND-
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CHAPTER 1: STATEMENT OF SPECIFIC AIMS 
Healthcare associated infections (HAIs) are a substantial source of morbidity and 
mortality, are considered one of the most common sources of preventable harm in the inpatient 
setting, and pose a major burden on the United States healthcare system.1-5 In 2015, it was 
estimated that 3.2% of patients, or roughly 1 in every 31 hospitalized adults, has at least one HAI 
on any given day in the US, which corresponds to almost 700,000 infections a year.2 Three major 
types of HAIs include urinary tract infections (UTIs), pneumonia, and bloodstream infections 
(BSIs). These infections can be largely classified as being either device associated, specifically 
catheter associated UTIs (CA-UTIs), ventilator associated pneumonia (VAP), and central line 
associated BSIs (CLA-BSIs), or non-device associated (ND-HAIs), which are defined as HAIs 
that occur when the devices listed above are not present.  
Historically, devices have been considered one of the biggest risk factors for HAIs 
(causing the vast majority of infections), and since the 1990s, surveillance programs managed by 
the Centers for Disease Control and Prevention (CDC) have focused on these infections to 
maximize efficiency.5-7 Subsequently, research and evidence-based prevention guidelines have 
also focused on CA-UTI, VAP, and CLA-BSI.8-11 In the past 10 years, there have been 
substantial decreases in the rates of device associated HAIs, largely driven by this research and 
the identification of successful prevention strategies which target the placement, maintenance, 
removal, and properties of the associated devices.1,2,6,12 Unsurprisingly, these interventions have 




the HAI burden in US hospitals.7,13-17 However, despite this growing impact, little is known 
about ND-HAIs infections. 
Thus, the overall goals of this research are to estimate the incidence of ND-HAIs, assess 
any changes in their rates over time, and to identify modifiable and non-modifiable risk factors 
for non-device associated HAIs, specifically non-device associated UTIs (ND-UTIs), non-device 
associated pneumonia (ND-pneumonia), and non-device associated BSIs (ND-BSIs). 
  
1.1 SPECIFIC AIM 1 
Describe the epidemiology of ND-HAIs- specifically ND-UTIs, ND-pneumonia, and 
ND-BSIs, in hospitalizations of non-prisoner adults (≥18 years old) admitted to University of 
North Carolina (UNC) Hospitals between 2012-2017. Calculate quarterly incidence rates of ND-
HAIs and the proportion of HAIs that are device- and non-device associated, and assess temporal 
trends during this time. Additionally, part of this investigation will explore how the rates of ND-
HAIs change depending on whether they are defined as the number of infections per: 
(1) All-hospitalization days (CDC definition)18 
(2) At-risk days only 
(3) At-risk, non-device days only 
 
1.2 SPECIFIC AIM 2 
Assess the association between patient demographics, comorbidities, illness severity, and 
inpatient treatments (medication use, device-use, procedures) and the incidence of ND-HAIs, 




Hospitals between 2015-2017. This aim will be composed of three separate analyses, for each 
ND-HAI: 
(1) Non-device associated urinary tract infections (ND-UTIs), 
(2) Non-device associated pneumonia (ND-pneumonia), and 
(3) Non-device associated bloodstream infections (ND-BSIs). 
Each infection type will have its own list of potential risk factors and will reflect relevant 
(i.e. non-device associated) risk factors for the device associated HAI counterpart (e.g. CA-UTI 
risk factors will be included in ND-UTI analysis), as well as other potentially clinically relevant 






CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 BACKGROUND 
Healthcare associated infections pose a significant burden on the healthcare system. 
Healthcare associated infections (HAIs) are a substantial source of morbidity and 
mortality, are considered one of the most common sources of preventable harm in the inpatient 
setting, and pose a major burden on the United States healthcare system.1-5 In 2015, it was 
estimated that 3.2% of patients, or roughly 1 in every 31 hospitalized adults, has at least one HAI 
on any given day in the US, which corresponds to almost 700,000 infections a year.2 In national 
hospital prevalence surveys conducted in 2011 and 2015 by the Centers for Disease Control and 
Prevention (CDC), the mortality rate of HAIs was estimated to be over 10%1,2, although it does 
vary based on the type of infection and patient-specific factors4,19-21. HAIs have also been found 
to cause prolonged lengths of stay (LOS)5,20,22,23, although the magnitude of their impact on LOS 
is somewhat unclear due to inappropriate methodology that overestimates the effect24,25. Overall, 
it is estimated that HAIs cost the US healthcare system between $3.2 to $9.8 billion dollars a 
year.5,23 
 
The shifting landscape of healthcare associated infections. 
Between 1992 and 1998, reports from the National Nosocomial Infection Surveillance 
(NNIS, a voluntary network of US hospitals collaborating with the CDC to monitor HAIs that 




(formerly referred to as nosocomial infections) were attributed to just three infection types- 
urinary tract infections (UTIs), pneumonia, and bloodstream infections (BSIs).26,27 Moreover, the 
same system found that 97% of UTIs were catheter associated UTIs (CA-UTIs), 83% of 
pneumonia cases were ventilator associated pneumonia (VAP), and 87% of BSIs were central 
line associated BSIs (CLA-BSIs).26 These findings shifted support among hospitals in NNIS 
from comprehensive (i.e. all HAIs) and hospital-wide (i.e. all units and patients) surveillance to 
more efficient, targeted surveillance, and by 1998 NNIS officially switched practices.21,28 In fact, 
targeted surveillance is still the standard today, and currently, the National Healthcare Safety 
Network (NHSN, established in 2005 and replaced NNIS), national reporting is only required for 
CA-UTIs and CLA-BSIs, as well as surgical site infections (SSIs) after colon surgery and 
abdominal hysterectomy, positive blood cultures for methicillin-resistant Staphylococcus aureus, 
and positive cultures for Clostridium difficile.6,7,29 Reporting of  VAP is supported, but is not 
currently required.  
 In 2011, the CDC conducted a multistate prevalence survey in order to estimate the total 
burden of HAIs at acute care hospitals, given that national surveillance no longer captured all 
infections.1,2 This survey found that the overall incidence of HAIs was 4.0% (95% confidence 
interval [CI] 3.7, 4.4), and that CA-UTI, VAP, and CLA-BSI, the infections that ‘have 
traditionally been the focus of programs to prevent health care associated infections’ now only 
accounted for 26% of all HAIs in the US that year.1 This dramatic decrease in device associated 
HAIs is likely due to the evidence-based guidelines on how to reduce CA-UTIs8, VAP9,10, and 
CLA-BSIs11 that the CDC released in the decade prior. Moreover, when the same survey was 
performed again in 2015, they found the HAI rate had decreased to 3.2% (95% CI 2.9, 3.5), and 




[RR] 0.84, 95% CI 0.74, 0.95).2 The study also found that 61% of pneumonia cases were non-
device associated (67 infections vs. 43 infections) and 38% of UTIs were non-device associated 
(21 vs. 34); almost all BSIs were CLA-BSI (42 out of 50 BSIs).2  
 
Epidemiology of non-device associated healthcare associated infections 
 Despite the changing landscape of HAIs and the role ND-HAIs now play in the incidence 
of hospital infections, relatively little is known about the incidence and epidemiology of these 
infections in the US. Additionally, of the studies that do exist on ND-UTIs, ND-pneumonia, and 
ND-BSIs, the majority are either dated or have used flawed methods for identifying HAIs.7,13-
17,30  
Several of these studies have come from the University of North Carolina (UNC) 
Hospitals, which has conducted comprehensive, hospital-wide surveillance of all HAIs (device 
and non-device associated) in accordance with CDC definitions and methodology since 1978.13,31 
From 2006-2009, they found that 28% of all UTIs were non-device associated, an ND-UTI rate 
of 6.4 infections per 10,000 non-device days14, and in 2010 ND-UTIs accounted for 38% of all 
urinary infections.13 Additionally, in 2010 ND-BSIs accounted for 22% of all BSIs and ND-
pneumonia accounted for 30% of all pneumonia cases.13 Finally, DiBiase et al. reported that 
from 2008-2012, the rates of CA-UTI, CLA-BSI, and VAP decreased significantly (similar to 
other findings), but that ND-UTI, ND-BSI, and ND-pneumonia rates remained consistent.7 
Overall, while these studies use robust methods for capturing infections and support the growing 
need to measure ND-HAI incidence and identify prevention strategies, whether these trends have 




 There have also been a handful studies estimating the incidence of ND-pneumonia from 
other research teams which assessed rates across multiple institutions15,17 or by utilizing a 
nationally available database of hospital discharge records (e.g. National Inpatient Sample)16. 
Davis and Finley (2012) utilized state-mandated comprehensive surveillance data from 
Pennsylvania, and found that between 2009 and 2011 that 71% of cases of pneumonia were non-
device associated (5,597 ND-pneumonia, 2,299 VAP), and that mortality rates were similar 
between the two groups (18.7% and 18.9%, respectively).15 In a 2014 convenience sample of 21 
hospitals across the US, the rate of ND-pneumonia ranged from 0.12 to 2.28 cases per 1,000 
patient days, and that all units have some risk for ND-pneumonia.17 There was also a study 
which estimated the rate of ND-pneumonia in 2012 was to be 3.36 per 1,000 hospital days; 
however, this is likely overestimated because of how they identified their ND-pneumonia 
cases.16  
Giuliano et al. (2017)16 conducted their study in the National Inpatient Sample (NIS, a 
stratified random sample of hospital discharges in the US), and had to identify ND-pneumonia 
cases using International Classification of Diseases, 9th Edition, Clinical Modification (ICD-9-
CM) diagnosis codes to identify cases of ND-pneumonia, which is problematic for a few reasons. 
First, several systematic reviews have found that administrative codes are poor predictors of 
HAIs, which can cause a high prevalence of false positives.32-34 Additionally, there appears to 
have been a shift in coding practices during this time period where hospitalizations of patients 
with community-acquired pneumonia, would have their infection coded secondary to more 
severe complications of the disease, like respiratory failure, sepsis, and pleural effusion.35 These 
coding changes would also increase the rate of false positives utilizing ICD-9-CM codes on 




Finally, to date, there have been no studies on the risk factors of ND-UTIs or ND-BSIs in 
the US. And while a few studies have looked at the effect of oral care on ND-pneumonia30,36,37, 
there are still no evidence-based guidelines for preventing ND-pneumonia, and other risk factors 
(and potential prevention strategies) remain essentially unknown.38 
 
2.2 SUMMARY 
HAIs represent a substantial source of morbidity and mortality, and are one of the most 
common sources of preventable harm in the inpatient setting.1-5 In the US, changes in HAI 
surveillance practices from comprehensive and hospital-wide to targeted in the 1990s have 
resulted in HAI efforts to focus on device associated infections (CA-UTIs, VAP, and CLA-
BSIs).21 Moreover, as significant reductions in the rates of device associated HAIs over the past 
decade have been seen, ND-HAIs rates have remained stagnant1,2,7 and ND-UTIs, ND-
pneumonia, and ND-BSIs now represent a growing proportion of all hospital infections.1,7,13-15 
And despite the growing need to understand the epidemiology of ND-HAIs, there is a paucity of 






CHAPTER 3: STUDY METHODOLOGY 
 
3.1 DATA SOURCES 
Carolina Data Warehouse for Health (CDW-H) 
Electronic medical records (EMR) from non-prisoner adults (≥18 years old) admitted to 
the University of North Carolina (UNC) Hospitals between January 1, 2013 and December 31, 
2017 were obtained from the Carolina Data Warehouse for Health (CDW-H), a central repository 
for clinical and administrative data from the UNC Healthcare System. Patients were allowed to 
have multiple hospitalizations during the study period.  
Among patients all patients, medical record numbers (MRNs), full name, date of birth, 
admission and discharge dates for inpatient hospitalizations were obtained from either the legacy 
healthcare system or Epic healthcare system, which went live at UNC Hospitals on April 4, 
2014. Additionally, among patients admitted between 2015 and 2017 (i.e. years where all patient 
EMR were in Epic), patient demographics, inpatient procedures, dispensed inpatient 
medications, laboratory test results, hospital locations throughout the entire hospitalization, 








UNC Hospitals Epidemiology Database 
UNC Hospitals Epidemiology database is a database of all HAIs, including both device 
and non-device associated HAIs, captured through comprehensive, hospital-wide active 
surveillance, in accordance with the Centers for Disease Control and Prevention (CDC) case 
definitions and methodology since 1978.13,31 Variables included in the Hospital Epidemiology 
database include: MRN, full name, date of birth, admission date, date of HAI diagnosis, infection 
site (UTI, pneumonia, or BSI) and device status (i.e. device or non-device associated).  
 
3.2 DATA LINKAGING 
Overall, there were 163,389 hospitalization records obtained from the CDW-H and 2,853 
HAIs captured in the Hospital Epidemiology database. These two data sources were then 
deterministically linked using combinations of medical record numbers (MRNs), date of 
admission, and/or first and last names. UTIs, pneumonia cases, and BSIs were linked to 
hospitalization records separately, 93% (n=2,651) HAIs were able to be linked using the full 
admission date (month, day, and year) and MRN in both data sources. Additionally, 2% (n=63) 
of records were linked using full admission date and full name, 4% (n=123) were linked using 
the full admission date, first name, and last name, and <1% (n=8) were linked using admission 
month and year only and MRN.  
Initially, 10 infections (5 UTIs, 3 pneumonia cases, and 2 BSIs) were unable to be linked. 
These records were then manually reviewed using chart review to identify additional MRNs or 






3.1 STUDY POPULATION 
All hospitalizations of non-prisoner adults (≥18 years old) admitted between January 1, 
2013 and December 31, 2017 were included. Patients will be allowed to contribute multiple 
hospitalizations during this time. Only patients admitted for ≥2 days (i.e. those at risk for an HAI 
as per CDC definitions18) and admitted between January 1, 2015 and December 31, 2017 were 
included for the risk factor analyses, as several variables of interest were either not recorded or 
not extractable from the legacy healthcare system.  
 
3.2 CALCULATING INCIDENCE RATES 
For Aim 1, quarterly incidence rates for ND-HAIs were calculated between 2013 and 
2017, and expressed as the number of infections per 10,000 hospitalization days. Hospitalization 
days will be defined using CDC definitions, which means that all hospitalization days, 
irrespective of patient risk or ND-HAI status, were included.18 For each hospitalization, 
admission and discharge dates were used to allocate person-time to each quarter. Patients could 
contribute multiple ND-HAIs at each site to the numerator.  
Poisson regression was used to assess potential linear trends in the quarterly rates of ND-
UTIs, ND-pneumonia, and ND-BSIs during the 5-year study period. The model used to assess 
said trends is detailed below. 
log(𝜇) =  𝑿𝒊𝜷 +  log(𝑛), where i = 1, … , 20 
 
log(𝜇) is the log rate of non-device associated HAI 









𝛿1𝑖 =  𝑞𝑢𝑎𝑟𝑡𝑒𝑟, when 𝑦𝑒𝑎𝑟 = 2010 (i. e. 1, 2, 3, or 4), and  
       = ((𝑦𝑒𝑎𝑟 − 2010) × 4) + 𝑞𝑢𝑎𝑟𝑡𝑒𝑟, when year > 2010 (i. e. 5, 6, … , 20) 
 
𝜷 =  (𝛽0 𝛽1)
′ is the 2 × 1 vector of unknown regression parameters: 
• β0 is the log rate of ND-HAIs in January-March 2010 
• β1 is the increment in the log rate of ND-HAIs for every quarter after January-March 
2010, assuming the rate increases linearly 
 
log(𝑛) is log of the number of patients admitted each quarter (i.e. offset) 
  
Two sensitivity analyses on the denominator definitions were also conducted. First, 
among hospitalizations between 2013 and 2017, rates of ND-HAIs per 10,000 at-risk 
hospitalization days were calculated to observe the impact of including not-at-risk time in the 
CDC-definition rates. For these rates, patients began contributing person time after being 
hospitalized for 2 days (i.e. the first 2 days are excluded), as per CDC definitions for HAIs, and 
stopped contributing person-time after they become infected with their first ND-HAI at the site 
of interest. Only a patient’s first ND-HAI for each site was included in the numerator. While in 
practice a patient is able to re-enter the at-risk pool after their ND-HAI is treated (and why 
patients are able to have multiple ND-HAIs at the same site in a single hospitalization), we were 





 Finally, among hospitalization between 2015 and 2017, rates of ND-HAIs per 10,000 
non-device days were also calculated. Non-device days were obtained by removing device days- 
obtained from the lines, drains, and airway device data from the CDW-H- from the at-risk days 
calculated above. Similar to the 2-day lag after admission to meet the definition for an HAI, the 
CDC also applies a 2-day lag on device-days, where an infection occurring within 2 days of a 
device being placed would not be associated with the new device, and any infections occurring 
within 2 days of a device being removed would be affiliated with said device. This criteria was 
also taken into account when calculating non-device day rates. Only a patient’s first ND-HAI at 
each site will be included in the numerator. Rates of device associated HAIs per 10,000 device 
days were also be calculated for this time period. 
 
3.3 MEASURING POTENTIAL RISK FACTORS 
Multivariable Cox proportional hazards regression was used to estimate the direct effect 
of potential risk factors on the incidence of ND-UTIs, ND-pneumonia, and ND-BSIs. Only a 
patient’s first HAI (device or non-device associated) was included. Correlation between repeat 
hospitalizations of the same patients were taken into account by the utilizing robust sandwich 
covariance matrix estimates described by Lee et al. (1992).39 Both inpatient mortality and device 
associated infections were treated as a competing risk using the Fine and Gray (1999) model, and 
the outcome of interest was categorized as censored (no event and no competing risk), event 
(ND-HAI), or competing risk (death or device associated HAI).40 The hazard at time t can be 
written out as follows: 





𝜆0(𝑡) is the expected or baseline hazard at time t  
X is an ni × k known fixed effects design matrix, where k is the number of risk factors included in 
the model, and  
β is the k × 1 vector of unknown fixed effect regression parameters 
 
Potential risk factors for each ND-HAI will be determined by identifying all known risk 
factors for device associated HAI counterpart (e.g. CA-UTI risk factors for ND-UTI) and other 
factors were identified through expert opinion (DJW, EESW, MK, AM).  
 
Patient Demographics 
 Patient age and sex were included in all three risk-factor analyses. Age was categorized 
by decade (18-29 years old [reference], 30-39 years old, 40-49 years old, 50-59 years old, 60-69 
years old, 70-79 years old, and ≥80 years old). Patient race was also captured and categorized as 
White [reference], Black, or Other race. Information on race was missing from 3% 
hospitalizations (n=2,820).  
 
Patient Comorbidities 
 Patient comorbidities were captured using the discharge diagnosis ICD-9-CM (January 
2015 – September 2015) and ICD-10-CM (October 2015 – December 2017) codes on each 
record. Deyo et al. (1992) and Quan et al. (2005) algorithms were adapted to identify  
components of the Charlson comorbidity index (CCI) score.41,42 Diagnosis codes for incident 
events (e.g. acute myocardial infarction) were dropped from all component definitions, as codes 




from analyses due to low incidence (n=201) and human immunodeficiency viruses (HIV) was 
incorporated into the broader classification of ‘immunocompromised’ (described below).  
 Immunocompromised patients were defined using the Advisory Committee on 
Immunization Practices (ACIP) and Infectious Diseases Society of America (IDSA) 
classification, which is used to identify persons who cannot receive live-attenuated vaccinations 
(e.g. chickenpox).43  Diagnoses of immunosuppressive conditions were identified using 
discharge diagnosis codes; relevant ICD-9-CM codes were identified using the Greenberg et al. 
(2016)44 algorithm and ICD-10-CM codes were identified from that list using General 
Equivalence Mappings (GEMS). Patients receiving chemotherapeutic agents, corticosteroids, or 
immune-modulating agents were identified using inpatient medications fills during the first 2 
days of their hospitalization. A full list of diagnoses and medications used can be found in Tables 
3.1 and 3.2, respectively. 
In addition to diagnosis codes, neutropenia was also defined as having 2 labs with white 
blood cell [WBC] count <500 cells/mm3 during the first 2 hospitalization days. Medications and 
laboratory results were restricted to this timeframe in order to minimize the potential of 
misclassifying conditions and events occurring after an ND-HAI as a potential risk factor, which 
could bias results. Low albumin, also measured within 2 days of admission, was also assessed as 
a potential risk factor, and defined as <3.4 g/dL. Patients who did not undergo a blood test were 
assumed to have normal levels. 
 BMI was calculated using patient height and weight, and categorized as underweight 







Severity of Illness 
 Illness severity was captured using the Modified Early Warning System (MEWS) 
score45,46 and the Morse Fall Scale47,48, both of which are captured and calculated in Epic. The 
MEWS uses vital signs- specifically systolic blood pressure, heart rate, respiratory rate, 
temperature, level of consciousness, and hourly urine output (for two hours)- to detect patients at 
risk for imminent clinical deterioration.49 The Morse Fall Scale is a simple prediction score 
designed to identify patients at risk for falling in the hospital.  The Morse Fall Scale includes the 
following variables: history of falling, number of secondary diagnoses, whether ambulatory aid 
is needed, intravenous therapy/heparin lock, gait, and mental status.50 For each patient, the first 
MEWS and Morse Fall Scale score within the first 2 days of admission was captured and 
categorized using clinically relevant cut points (MEWS: <1 [reference], 2, 3, ≥4; Morse Fall 
Scale: 0 [reference], 1-24, 25-45, >45). A MEWS ≥4 and a Morse Fall Scale score >45 are both 
considered indicators of severe illness.49,50 
 
Inpatient Medication Use 
 Inpatient medications of interest included systemic antibiotics (all ND-HAIs), anesthetics 
(local and general, all ND-HAIs), benzodiazepines (all ND-HAIs), opioids (all ND-HAIs), 
anticholinergics (ND-UTIs, ND-BSIs only), alpha-2 agonists (ND-BSIs only), nonsteroidal anti-
inflammatory medications (NSAIDs, ND-BSIs only), calcium channel blockers (ND-BSIs only), 
and acid-suppressing medications (histamine-type 2 receptor blockers [H2 blockers] and proton 
pump inhibitors [PPIs], ND-pneumonia only). Total parenteral nutrition (TPN, all ND-HAIs) and 




factors and captured through inpatient medication files. Finally, inpatient urinary retention (ND-
UTIs only) was measured using suggestive medications for the disease.  Generic medication for 
all medications are described in Table 3.2.  
All medication administration, including TPN, chlorhexidine mouthwash, and urinary 
retention treatment, was confirmed using the medication administration record (MAR) and 
treated as a time-varying exposure, meaning patients were considered unexposed until the time 
of their first administration, and remained exposed for the remainder of follow-up. If a patient 
did not receive a medication until after their ND-HAI or device associated HAI event, they were 
considered unexposed for their entire at-risk time. 
 
Inpatient Procedures 
Current Procedural Terminology (CPT) codes were used to identify inpatient procedures 
that may be risk factors for ND-HAIs, specifically urologic surgery (ND-UTIs only), and dialysis 
(ND-pneumonia). Undergoing any surgical procedure (all ND-HAIs) was also assessed. 
Procedures were also treated as a time-varying exposure.  
 
Prior Device Use 
 Prior device use was also considered potential risk factors. Among ND-UTIs, urinary 
catheters (CA-UTI device), suprapubic catheters, and nephrostomy tubes were each assessed. 
Endotracheal tubes and tracheostomy (both VAP devices) were assessed as a potential risk factor 
for ND-pneumonia, and both central venous catheter (CVC, CLA-BSI device), and peripheral 






Other Variables of Interest 
 Other potential risk factors of interest include trauma admission (all ND-HAIs), hospital 
location/service (all ND-HAIs), being admitted for a urinary disease (ND-UTIs only), being 
admitted with pneumonia (ND-pneumonia) only, and prior HAI (device or non-device related) 
(ND-BSIs only). Service, specifically intensive care unit (ICU) , and prior HAI were treated as 
time-varying exposures. 
 
3.6. HANDLING MISSING DATA 
Due to missing values of BMI (n=15,146, 17%), MEWS (n=18,761, 21%), Morse Fall 
Scale (n=8,571, 10%), and location/discharge disposition (n=8,482, 10%), inverse-probability of 
missing weights (IPMW) were calculated.51 Weights were estimated using multivariable logistic 
regression, which modeled the probability of being a complete case as a function of the year and 
season of admission, cause of admission, patient age, sex, Charlson score comorbidities 
(excluding HIV and cancer), immunosuppression, TPN, target medication usage anytime during 
hospitalization (antibiotics, antipsychotics, local anesthetics, general anesthetics, 
benzodiazepines, opioids, alpha-2 agonists, NSAIDs, calcium channel blockers, statins, 
angiotensin converting enzyme [ACE] inhibitors, angiotensin II receptor blockers [ARBs], H2 
blockers, PPIs), device use (urinary catheter, ventilator, central venous catheter, peripheral 
venous catheter), whether they underwent any surgery (CPT 10021 – 69990), and LOS, as well 
as interaction terms between admission date (year and quarter) and both cause of admission and 
LOS. Age and LOS were modeled as restricted quadratic splines.52 Because 99% of 
hospitalizations from January-March 2015 were missing MEWS (28% of all the missing data), 




Table 3.1. International Classification of Diseases 9th and 10th edition, Clinical Modification 
(ICD-9-CM and ICD-10-CM) codes used to capture selected comorbidities and 
immunosuppressive conditions. 
 ICD-9-CM code(s) ICD-10-CM code(s) 
CCI comorbiditiesa   
History of MI 412 I25.2 
Congestive heart failure 428.0 – 428.9 I50.1 – I50.9 
Cerebrovascular disease 438.0 – 438.9 I69.00 – I69.998 
Dementia 290.0 – 290.9 F01.5 – F03.91 
Chronic pulmonary diseaseb 490 – 496, 500 – 505, 506.4 
J40 – J47.9, J60 – J67.9, 
J68.4 
Rheumatic disease 
710.0, 710.1, 710.4, 714.0 – 
714.2, 714.81, 725 
M05.00 – M05.9, M06.00 – 
M06.9 
Peptic ulcer disease 
531.4 – 531.7, 532.4 – 532.7, 
533.4 – 533.7, 534.4 – 534.7 
K25.4 – K25.7, K26.4 – 
K26.7, K27.4 – K27.7, 
K28.4 – K28.7 
Mild liver disease 571.2, 571.4 – 571.6 
K70.30, K70.31, K74.0, 
K74.3, K74.4, K74.5, 
K74.60, K74.69 
Moderate or severe liver 
disease 
572.2 – 572.8 
K72.10, K72.90, K72.91, 
K76.6, K76.7 
Diabetes without chronic 
complications 
250.0 – 250.3, 250.7 
E10.10, E10.11, E10.61 – 
E10.69, E10.8, E10.9, 
E11.00, E11.01, E11.10, 
E11.11, E11.61 – E11.69, 
E11.8, E11.9, E12.00, 
E12.01, E12.10, E12.11, 
E12.61 – E12.69, E12.8, 
E12.9, E13.00, E13.01, 
E13.10, E13.11, E13.61 – 
E13.69, E13.8, E13.9, 
E14.00, E14.01, E14.10, 
E14.11, E14.61 – E14.69, 
E14.8, E14.9 
Diabetes with chronic 
complication 
250.4 –250.6 
E10.21 – E10.29, E10.31 – 
E10.39, E10.40 – E10.49, 
E10.51 – E10.59, E10.71 – 
E10.79, E11.21 – E11.29, 
E11.31 – E11.39, E11.40 – 
E11.49, E11.51 – E11.59, 
E11.71 – E11.79, E12.21 – 
E12.29, E12.31 – E12.39, 
E12.40 – E12.49, E12.51 – 
E12.59, E12.71 – E13.79, 
E13.21 – E13.29, E13.31 – 




E13.51 – E13.59, E13.71 – 
E13.79, E14.21 – E14.29, 
E14.31 – E14.39, E14.40 – 
E14.49, E14.51 – E14.59, 
E14.71 – E14.79 
Hemiplegia or paraplegia 342.0 – 342.9, 344.1 G81.0 – G82.54 
Renal disease 
582.0 – 582.9, 583.0 – 583.7, 
585.1 – 585.9, 586, 588.0 – 
588.9 
N03.0 – N03.9, N05.0 – 
N05.9, N18.1 – N18.9, 
N19, N25.0 – N25.9 
Chronic pulmonary diseaseb   
Bronchitis/emphysemac 
490, 491.0 – 491.9, 492.0, 
492.8 
J40 – J44.1 
Asthmac 493.0 – 493.92 J45.20 – J45.998 
Bronchiectasisc 494.0, 494.1 J47.0 – J47.9 




HIV/AIDS 042, 079.53 B20 
Neutropenia 288.00 – 288.9 D70.0 – D70.9 
Organ transplant 
996.80 – 996.99, V42.0 – 
V42.9 
T86.00 – T86.99, Z94.0 – 
Z94.9 
Hematological malignancy 200.0 – 208.92 C81. 00 – C96.9 
Solid malignancy 
140.0 – 199.2, 209.0 – 
209.79, 235.0 – 239.9 
C00.0 – C80.2, C7A, C7B, 
D37.01 – D49.9 
Rheumatologic/inflammatory 
condition 
135, 277.30 – 277.39, 340, 
341.0 – 341.9, 357.0 – 357.9, 
422.0 – 422.99, 446.0 – 
446.7, 495.9, 516.0 – 516.9, 
555.0 – 558.9, 695.4, 710.0 – 
712.99, 714.0 – 714.9, 720.0 
– 720.9 
D86.0 – D86.9, E10.40, 
E10.42, E11.40, E11.42, 
E12.40, E12.42, E13.40, 
E13.42, E14.40, E14.42, 
E85.0 – E85.9, G35, G36.0 
– G36.9, G61.0 – G65.2, 
I40.0 – I40.9, I41, J67.9, 
J84.01 – J84.09, K50.00 – 
K52.9, K55.0 – K55.9, 
L93.0, L93.2,  M00.00 – 
M00.9, M01.X0 0 M01.X9, 
M02.10 – M02.19, M02.30 
– M02.39, M04.1, M05.00 
– M05.9, M06.00 – M06.9, 
M08.00 – M08.99, 
M11.00 – M11.9, M12.00 – 
M12.09, M30.0 – M30.8, 
M32.0 – M34.9, M35.00 – 
M35.3, M35.8, M35.9, 
M45.0 – M46.1, M46.50 – 
M46.59, M46.80 – M46.99, 




Other immune conditions 
279.0 – 279.9, 288.0 – 288.2, 
288.50 – 279.59, 288.8, 
288.9, 288.00 – 288.9, 
289.83, 289.89, 289.9, 
795.71, 795.79 
D47.4, D71, D72.0, 
D72.810 – D72.819, 
D72.89, D72.9, D75.81, 
D75.89, D75.9, D80.0 – 
D80.9, D89.2, R75, R76.0, 
R76.8, R76.9 
Cause of admission   
Trauma 800.0 – 959.9 
S00.00XA – T34.99XS, 
T79.0XXA – T79.9XXS 
Urologic diseasec 590.0 – 599.9, 996.64, 997.5 
N10 – N13.9, N16, N20.0 – 
N22, N28.0 – N37, N39.0 – 
N39.9, N99.0 – N99.89, 
T83.510 – T83.598S 
R80.2 
Abbreviations; ICD-9-CM, International Classification of Diseases, 9th edition, Clinical 
modification; ICD-10-CM, International Classification of Diseases, 10th edition, Clinical 
modification; CCI, Charlson Comorbidity Index; MI, myocardial infarction: HIV/AIDS, 
human immunodeficiency virus/acquired immunodeficiency syndrome 
a Only codes which could be applied to the index hospitalization were used; e.g. history of MI  
(ICD-9-CM 412) was included, but acute MI (ICD-9-CM 410-410.92) was excluded 
b For ND-pneumonia analyses only, chronic pulmonary disease were broken into smaller, 
more granular categories 







Table 3.2. Generic medication names used to identify and classify medications of interest.  
 Generic medication name(s) 
Antibiotics, systemic  
β-lactams Amoxicillin, Ampicillin, Benzathine penicillin, 
Dicloxacillin,  Nafcillin, Oxacillin, Penicillin G, Penicillin 
V,  Piperacillin 
Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefepime, 
Cefixime, Cefotetan, Cefoxatime, Cefoxitin, 
Cefpodoxime, Ceftriaxone, Ceftaroline, Ceftazidime, 
Cefuroxime, Cephalexin, Cepodoxime proxetil 
Aztreonam  
Ertapenem, Imipenem, Meropenem 
Avibactam, Clavulanic acid, Sulbactam  
Ampicillin/Sulbactam, Amoxicillin/Clavulanate, 
Ceftolozane/tazobactam, Piperacillin/Tazobactam 
Colistin (colistamethate sodium), Daptomycin, 
Ethambutol, Isoniazid, Polymyxin B, Pyrazinamide, 
Metronidazole  
Aminoglycosides Amikacin, Gentamicin,  Neomycin, Paromomycin, 
Tobramycin 
Chloramphenicol Chloramphenicol 
Glycopeptides Telavancin, Vancomycin 
Macrolides Azithromycin, Clarithromycin, Erythromycin,  
Fidaxomicin, Telithromycin 
Oxazolidinones Linezolid, Tedizolid  
Quinolones Ciprofloxacin,  Levofloxacin, Moxifloxacin, Ofloxacin 
Rifaximin Rifaximin 
Sulfonamides Sulfadiazine, Sulfamethoxazole, Trimethoprim  






General Etomidate, Ketamine, Midazolam, Propofol 
Local Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, 
Ropivacaine, Tetracaine 
Anticholinergics   
Antipsychotics/neuroleptics Amitriptyline, Aripiprazole, Chlorpromazine, Clozapine, 
Desipramine, Doxepin, Droperidol, Fluphenazine, 
Haloperidol, Imipramine, Lurasidone, Nortriptyline, 
Olanzapine, Paliperidone, Paroxetine, Perphenazine, 




Quetiapine, Risperidone, Thioridazine, Thiothixene, 
Trifluoperazine, Ziprasidone 
Other Amantadine, Atropine, Baclofen, Benztropine, 
Carisoprodol, Cetirizine, Chlorpheniramine, Colchicine, 
Cyclobenzaprine, Cyproheptadine, Dexchlorpheniramine, 
Dicyclomine, Digoxin, Diphenhydramine, Diphenoxylate, 
Darifenacin, Fesoterodine, Hydroxyzine, Hyoscyamine, 
Loperamide, Loratadine, Meclizine, Pseudoephedrine, 
Ranitidine, Scopolamine, Solifenacin, Tizanidine, 
Tolterodine, Trospium 
Antipsychotics/neuroleptics Amitriptyline, Aripiprazole, Chlorpromazine, Clozapine, 
Desipramine, Doxepin, Droperidol, Fluphenazine, 
Haloperidol, Imipramine, Lurasidone, Nortriptyline, 
Olanzapine, Paliperidone, Paroxetine, Perphenazine, 
Prochlorperazine, Promazine, Promethazine, Protriptyline,  
Quetiapine, Risperidone, Thioridazine, Thiothixene, 
Trifluoperazine, Ziprasidone 
Benzodiazepines Alprazolam, Chlordiazepoxide, Clobazam, Clomipramine, 
Clonazepam, Clorazepate, Diazepam, Flurazepam, 
Lorazepam,  Midazolam, Oxazepam, Temazepam 
Histamine 2-agonists Cimetidine, Famotidine, Ranitidine 
Proton pump inhibitors Dexlansoprazole, Esomeprazole, Lansoprazole, 
Omeprazole, Pantoprazole 
Opioids Buprenorphine, Codeine, Fentanyl, Hydromorphone, 
Meperidine, Methadone, Morphine, Nalbuphine, 
Oxycodone, Oxymorphone, Sufentanil, Tapentadol, 
Tramadol 




Chemotherapeutic agents  
(alkylating) 
Bendamustine hydrochloride, Busulfan, Carmustine,  
Cyclophosphamide, Darabazine, Ifosfamide, Melphalan, 
Thiotepa 
Chemotherapeutic agents  
(antibiotics) 
 Bleomycin sulfate, Dactinomycin, Daunorubicin, 
Doxorubicin, Epirubicin, Idarubicin 
Chemotherapeutic agents  
(antimetabolites) 
Capecitabine, Cladribine, Clofarabine, Cytarabine,  
Fludarabine, Fluorouracil, Gemcitabine, Mercaptopurine, 
Methotrexate, Pemetrexed, Pentostatin 
Chemotherapeutic agents  
(antimitotics) 
 Docetaxel, Paclitaxel, Vinblastine, Vincristine, 
Vinorelbine 
Chemotherapeutic agents  
(monoclonal antibodies) 
Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab,  
 Ofatumumab, Rituximab 
Chemotherapeutic agents 
(other) 
Aldesleukin,  Arsenic trioxide, Asparaginase, Azacitidine, 
Brentuximab vedotin, Bortezomib, Carboplatin, 
Carfilzomib, Cisplatin, Dasatinib, Decitabine, Erlotinib, 




Mitoxantrone, Nelarabine, Nilotinib, Oxaliplatin, 
Pazopanib, Pegaspargase,  Pralatrexate, Procarbazine, 
Romidepsin, Sorafenib, Sunitinib, Temozolomide, 
Temsirolimus,  Topotecan, Tretinoin, Vorinostat 
Immune-modulating agents Abatacept, Adalimumab, Alefacept, Anakinra,  
Azathioprine, Basiliximab, Belatacept, Belimumab, 
Certolizumab pegol, Cyclosporine, Daclizumab, 
Denosumab, Eculizumab, Efalizumab, Etanercept, 
Fingolimod, Glatiramer, Golimumab, Infliximab, 
Interferon alfa-2a, Interferon alfa-2b, Interferon alfa-n3, 
Interferon alfacon-1, Interferon beta-1a, Interferon beta-
1b, Interferon gamma-1b, Leflunomide, Lenalidomide, 
Muromonab-CD3, Mycophenolate acid, Mycophenolate 
mofetil, Natalizumab, Palifermin, Palivizumab, 
Pomalidomide, Pegademase bovine, Peginterferon alfa-2a, 
Peginterferon alfa-2b,  Sirolimus, Tacrolimus,  
Tocilizumab, Ustekinumab 
Systemic corticosteroids Betamethasone, Budesonide, Dexamethasone, 







CHAPTER 4: INCIDENCE AND RISK FACTORS OF NON-DEVICE ASSOCIATED 




Healthcare associated infections (HAIs) pose a major burden on the United States 
healthcare system.  HAIs are a substantial source of morbidity and mortality and are considered 
one of the most common sources of preventable harm in the inpatient setting.1-5,21 In 2015, 3.2% 
of patients, or roughly 1 in every 31 hospitalized adults, had at least one HAI on any given day in 
the US, which corresponds to almost 700,000 infections a year.2 Urinary tract infections (UTIs) 
are one of the most common types of HAIs, accounting for almost 15% of all HAIs and one-third 
of HAIs outside of intensive care units.1,2,21 And while mortality and cost of UTIs may be low 
(2% and $589, respectively), because they are so common the estimated overall burden is 
substantial (13,000 deaths and $340 million per year).21,53 
Historically the vast majority of UTIs have been considered catheter associated (CA-
UTIs).21,26,28  However, there is increasing appreciation that non-device associated UTIs (ND-
UTIs) account for a substantial fraction and sometimes the majority of hospital-onset UTIs.  
Rates of CA-UTIs have dramatically decreased over the past decade but the rate of non-device 
associated UTIs (ND-UTIs) have remained stagnant.2,7,13,14 Despite the increasing importance of 
ND-UTIs in the acute care setting, there is a paucity of research on the incidence, risk factors, 




update current estimates of ND-UTI rates and their frequency relative to CA-UTI, assess 
temporal trends, and identify potential risk factors for ND-UTI.  
 
4.2 METHODS 
Data sources and study population 
 Electronic medical records (EMR) from adults (≥18 years old) admitted to the University 
of North Carolina (UNC) Hospitals between January 1, 2013 and December 31, 2017 were 
obtained from the Carolina Data Warehouse for Health (CDW-H), a central repository for 
clinical and administrative data from the UNC Healthcare System. Prisoners were excluded from 
analysis. Patients were able to have multiple hospitalizations during the study period. HAIs were 
identified through the UNC Hospitals’ Infection Prevention database, which included both 
device and non-device associated HAIs, captured through comprehensive, hospital-wide active 
surveillance, in accordance with the Centers for Disease Control and Prevention (CDC) case 
definitions and methodology.13,31 The two databases were then deterministically linked using 
admission date, medical record numbers, and full name.  This study was approved by the UNC 
Institutional Review Board.  
 
Incidence of ND-UTIs 
 Quarterly incidence rates, per 10,000 hospitalization days, between 2013 and 2017 were 
calculated and Poisson regression was used to estimate potential changes in ND-UTI rates over 
time. The proportion of UTIs that were non-device related each year were also calculated. 
Cochran-Armitage trend tests (two-sided) were used to test the null hypothesis that the 





Risk Factors for ND-UTIs 
 Only hospitalizations between 2015 and 2017 with a length of stay (LOS) >2 days were 
included in the risk factor analysis. Potential risk factors of interest included patient sex, age 
(categorized as 18-39 years old [reference], 40-49 years old, 50-59 years old, 60-69 years old, 
and ≥70 years old), selected comorbidities, immunosuppression, BMI (categorized as 
under/normal weight [<25, reference], overweight [25.0 – 29.9], and obese [≥30.0]), trauma 
admission, being on an intensive care unit (ICU), Modified Early Warning Score, Morse Fall 
scale, urinary retention, inpatient medications (anesthesia antibiotics, anticholinergics, 
benzodiazepines, and opioids), total parenteral nutrition (TPN), urinary catheterization, 
suprapubic catheterization, nephrostomy tube, and having underwent a urologic procedure.  
Patient comorbidities were identified using the discharge diagnosis ICD-9-CM (January 
2015 – September 2015) and ICD-10-CM (October 2015 – December 2017) codes on each 
record. Deyo et al. (1992) and Quan et al. (2005) algorithms were adapted to identify 
components of the Charlson comorbidity index (CCI) score (Table 4.1).41,42 Diagnosis codes for 
incident events (e.g. acute myocardial infarction) were removed from all component 
definitions.41 Peripheral vascular disease (PVD) was also excluded due to low incidence (n=201) 
and both malignancy (solid tumor or metastatic disease) and human immunodeficiency viruses 
(HIV) were incorporated into the broader classification of immunocompromised.  
Immunocompromised patients were identified using the Advisory Committee on 
Immunization Practices (ACIP) and Infectious Diseases Society of America (IDSA) guidelines, 
which are used to determine persons who cannot receive live-attenuated vaccinations.43  




transplant, and any malignancy- were identified using discharge diagnosis codes; relevant ICD-
9-CM codes were identified using the Greenberg et al. (2016)44 algorithm and ICD-10-CM codes 
were identified using CMS General Equivalence Mappings (GEMS) (Table 4.1). Patients 
receiving chemotherapeutic agents, corticosteroids, or immune-modulating agents within the first 
2 days of their hospitalization were identified using inpatient medications (Table 4.2). 
Neutropenia was identified using both diagnosis codes and laboratory blood test results within 
the first 2 hospitalization days (defined as ≥2 white blood cell [WBC] counts <500 cells/mm3). 
Urinary retention was identified through inpatient medication treatment for the condition (Table 
4.2). 
Severity of illness was captured using the Modified Early Warning Score (MEWS)45,46 
and Morse Fall Scale47,48, which are captured and calculated within the UNC Hospitals EMR. 
The MEWS uses vital signs- specifically systolic blood pressure, heart rate, respiratory rate, 
temperature, level of consciousness, and hourly urine output (for two hours)- to detect patients at 
risk for imminent clinical deterioration.49 The Morse Fall Scale is a simple prediction score 
designed to identify patients at risk for falling in the hospital.  The Morse Fall Scale includes the 
following variables: history of falling, number of secondary diagnoses, whether ambulatory aid 
is needed, intravenous therapy/heparin lock, gait, and mental status.50 For each patient, the first 
MEWS and Morse Fall Scale score within the first 2 days of admission was captured and 
categorized using clinically relevant cut points (MEWS: <1 [reference], 2, 3, ≥4; Morse Fall 
Scale: 0 [reference], 1-24, 25-45, >45). A MEWS ≥4 and a Morse Fall Scale score >45 are both 
considered indicators of severe illness.49,50 
ICU stay, urinary retention, inpatient medications, TPN, device use, and urologic 




for the remainder of the hospitalization. For example, once a patient received antibiotics on day 
4, they were considered to be exposed from day 4 until discharge, and were classified as 
unexposed on days 1-3. All medications were identified using orders captured in the EMR and 
receipt was confirmed using the medication administration record (Table 4.2). Urinary retention 
was captured through treatment (Table 4.2), and urologic procedures were identified using CPT 
codes 50010 – 53899. 
Multivariable Cox proportional hazards regression was used to simultaneously estimate 
the association between each potential risk factor and the incidence of ND-UTIs. Correlation 
between repeat hospitalizations of the same patients were taken into account by utilizing robust 
sandwich covariance matrix estimates as described by Lee et al. (1992) and CA-UTI and 
inpatient mortality were treated as competing risks using the Fine and Gray (1999) model.39,40 
Due to missing values of BMI (n=15,146, 17%), MEWS (n=18,761, 21%), Morse Fall 
Scale (n=8,571, 10%), and location/discharge disposition (n=8,482, 10%), inverse-probability of 
missing weights (IPMW) were calculated.51 Weights were estimated using multivariable logistic 
regression, which modeled the probability of being a complete case as a function of the year and 
season of admission, cause of admission, patient age, sex, Charlson score comorbidities 
(excluding HIV and cancer), immunosuppression, TPN, target medication usage anytime during 
hospitalization (antibiotics, antipsychotics, local anesthetics, general anesthetics, 
benzodiazepines, opioids, alpha-2 agonists, non-steroid anti-inflammatory drugs [NSAIDs], 
calcium channel blockers, statins, angiotensin converting enzyme [ACE] inhibitors, angiotensin 
II receptor blockers [ARBs], histamine-2 agonists, proton pump inhibitors), device use (urinary 
catheter, ventilator, central venous catheter, peripheral venous catheter), whether they underwent 




(year and quarter) and both cause of admission and LOS. Age and LOS were modeled as 
restricted quadratic splines.52 Because 99% of hospitalizations from January-March 2015 were 
missing MEWS (28% of all the missing data), all hospitalizations in this time period were 
excluded from multivariable analysis. 
Our statistical analysis strategy is consistent with the American Statistical Association’s 
statements on p-values.54,55 All statistical computations were performed using SAS 9.4 (SAS 
Inc., Cary, NC). 
 
4.3 RESULTS 
 From 2013-2017 there were 163,386 hospitalizations (97,485 unique patients) and 1,273 
UTIs (715 ND-UTI, 558 CA-UTI) during 1,234 unique hospitalizations at UNC Hospitals. Of 
the 1,273 UTIs, 1,268 (99.6%) were successfully linked to a hospitalization record. 87% 
(n=142,836) of hospitalizations were >2 days (median 5 days, interquartile range [IQR] 3-8 
days). Patient demographics and causes of admission are described in Table 4.3.  
Median time to first UTI was 8 days for both ND-UTIs (IQR 4 -15) and CA-UTIs (IQR 
4-18). Between 2013 and 2017, the rate of ND-UTIs decreased slightly but overall remained 
stable, with 6.14 ND-UTIs per 10,000 hospitalization days in 2013 and 5.57 ND-UTIs per 
10,000 hospitalization days in 2017, p=0.15 (Figure 4.1.A). However, the proportion of UTIs 
that were non-device related increased from 52% to 72% during this time, p<0.0001 (Figure 
4.1.B). From 2015-2017, 15% (n=49) of ND-UTIs occurred in an ICU, 70% (n=229) occurred on 
a floor, and 14% on a stepdown unit (n=46) (67 could not be classified due to missing location 
data). In comparison, 55% of CA-UTIs occurred in an ICU (n=137), 32% on the floor (n=81), 




cumulative incidence of ND-UTI was 19.9 and 48.7 infections per 10,000 patients, respectively 
(Figure 4.2). 
 There were 88,487 hospitalizations between 2015 and 2017 with a LOS >2 days included 
in the risk factor analysis. Median IPMW was 1.07 (IQR 1.03-1.24, range 1.00 – 21.38); only 27 
hospitalizations had a weight >10. After adjustment, female sex (HR 1.94, 95% CI 1.50, 2.50) 
and increasing age, with patients ≥70 years, compared to 18-25 year old patients, old having the 
highest incidence (HR 2.06, 95% CI 1.33, 3.21) were associated within increased incidence of 
ND-UTIs, Table 4.4. Moreover, the effect of female sex appeared to be relatively consistent 
across age (p=0.57). Patients diagnosed with peptic ulcer disease (HR 2.25, 95% CI 1.04, 4.86) 
or who were immunosuppressed (HR 1.48, 95% CI 1.15, 1.91) were also at higher risk for ND-
UTIs. Trauma admissions were associated with increased patient risk for ND-UTI (HR 1.36, 
95% CI 1.02, 1.81). BMI and MEWS did not appear to have any impact.  
 During the hospitalization, being given TPN (HR 1.99, 95% CI 1.35, 2.94) and opioids 
(HR 1.62 95% CI 1.10, 2.32) were associated with increased patient risk of ND-UTI, Table 4.4. 
In the crude analyses, urinary retention, suprapubic catheterization, and nephrostomy tubes were 
associated with increased risk of infection, but after adjustment for possible confounders, 
confidence intervals were wide and effects were no longer statistically significant (urinary 
retention: HR 1.41, 95% CI 0.96, 2.07, suprapubic catheterization: HR 2.28, 95% CI 0.88, 5.91 
and  nephrostomy tubes: HR 2.02, 95% CI 0.83, 4.93). Local anesthesia (HR 0.70, 95% CI 0.53, 
0.92), antibiotics (HR 0.32, 95% CI 0.24, 0.43), non-antipsychotic anticholinergics (HR 0.68, 
0.53, 0.87), and benzodiazepines (HR 0.66, 0.51, 0.87) were associated with reduced risk of 






 Between 2013 and 2017, the incidence of ND-UTIs have remained consistent and 72% 
UTIs are now non-device associated. Females, older adults, peptic ulcer disease, paralysis, 
immunosuppression, urinary retention, opioid use, TPN, and trauma patients all had a higher risk 
of ND-UTI. Suprapubic catheters and nephrostomy tubes may also increase patient risk. To the 
best of our knowledge, this is the first study to conduct a robust and in-depth analysis of ND-UTI 
risk factors and most recent assessment of ND-UTI incidence. 
 Over the past decade, the rate of ND-UTIs has remained relatively consistent but the 
relative burden of non-device associated has increased. For example, from 2006-2009, 28% of all 
UTIs at UNC Hospitals were non-device associated and the rate of ND-UTIs was 6.4 infections 
per 10,000 non-device days14, but by 2012 it rose to almost 50%.7 As of 2017, the rate of ND-
UTI was 5.57 ND-UTIs per 10,000 hospitalization days and 3 out of every 4 UTIs were non-
device associated. This shift towards non-device infections is likely due to implementation of 
evidence-based guidelines to prevent CA-UTI; these guidelines mainly target catheter placement, 
maintenance, and removal and thus have limited impact on preventing ND-UTIs.8,56 Our results 
suggest that current targeted surveillance practices directed at catheterized patients alone are no 
longer sufficient to capture the majority of UTIs in acute care settings.  
 We found that patient demographics and comorbidities, specifically female sex, older 
age, peptic ulcer disease, paralysis, and immunosuppression, were associated with increased ND-
UTI incidence. Female sex, older age, paraplegia, and immunosuppression have also been shown 
to increase the risk for CA-UTIs, indicating that certain subsets of patients may be at higher risk 
for all UTIs.57-59 However, a recent study of CA-UTI found that after accounting for 




likely means that age is a proxy for illness severity or frailty, and not an independent risk factor 
itself59. To the best of our knowledge, peptic ulcer disease has not been reported to be a risk 
factor for UTIs (or CA-UTIs), but treatments such as ranitidine, may cause drug-induced urinary 
retention, particularly in new users, females, and those ≥60 years old.60,61 However, peptic ulcer 
disease was associated with ND-UTI incidence even after adjusting for urinary retention, 
indicating that other factors may also be at play. 
 Inpatient medication use was also associated with ND-UTI incidence.  Patients receiving 
antibiotics, local anesthetics, anticholinergics, and benzodiazepines were at reduced risk for 
infection, and patients receiving TPN and opioids were at increased risk. Opioids have also been 
found to cause drug-induced urinary retention60, although opioid use may also be a proxy for 
acute pain and limited mobility (particularly after surgery), which may increase risk for UTIs, 
particularly in older adults62. Several studies have also found that TPN was associated with 
increased fungal infections, including UTIs, in hospitalized patients.63,64 Interestingly, we found 
that antibiotic use was associated with reduced incidence of ND-UTIs although antibiotic 
prophylaxis has not been found to reduce risk of CA-UTIs.8 And while local anesthetics, 
anticholinergics, and benzodiazepines are also known to cause urinary retention, anesthetics and 
benzodiazepines were associated with reduced risk of ND-UTIs, even in unadjusted analyses. It 
is possible that patients receiving these medications may represent an overall healthier patient 
population.  
 Finally, both suprapubic catheters and nephrostomy tubes were associated with increased 
incidence of ND-UTIs, but estimates were imprecise. A recent Cochrane review (2015) found 
that there was little or no difference in symptomatic UTI risk between short-term suprapubic 




longer durations, which could explain the higher cumulative infection risk in this population.65 
Currently, neither suprapubic catheters nor nephrostomy tubes are included in the CDC CA-UTI 
definition, and the CDC has no recommendations for preventing CA-UTI in these populations, 
although they do call for further research on the topic.8 
 This study is not without limitations. First, this was a retrospective, single center study 
and our results may not generalize to other hospitals, particularly if the patient population is 
different. We also did not account for duration, dose, or underlying indications for medication 
use. Future studies should assess whether longer exposures or higher doses of opioids and other 
medications are associated with higher risk for ND-UTI. Additionally, ICD-9-CM and ICD-10-
CM codes were used to identify most comorbidities. Using these codes likely underestimates the 
prevalence of comorbidities, although we expect this misclassification to be non-differential and, 
if anything, bias results towards the null. Similarly, ND-UTIs and CA-UTIs were captured using 
CDC definitions, which require laboratory confirmation.  Patients who are treated for suspected 
UTIs but are not cultured would be missed.  Likewise, urinary retention was captured using 
suggestive medications and thus patients managed without medications would also be missed. 
Finally, although we had a large sample size, the incidence of ND-UTI and prevalence of some 
risk factors were low, resulting in low levels of precision of the estimators as indicated by the 
widths of the observed confidence intervals.   
 In conclusion, between 2013 and 2017, the incidence rate of ND-UTIs remained 
relatively stable, although non-device infections now represent the majority of UTIs in our acute 
care hospital. Current targeted surveillance practices for catheter associated UTIs should be 
reconsidered in light of this changing landscape. Women, older age, peptic ulcer disease, 




factors for ND-UTI. Urinary retention, suprapubic catheters and nephrostomy tubes may also 
increase patient risk. Future research should attempt to replicate these findings and explore the 
impact of prevention strategies that target these risk factors.   
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Table 4.1. International Classification of Diseases 9th and 10th edition, Clinical Modification 
(ICD-9-CM and ICD-10-CM) codes used to capture selected comorbidities and 
immunosuppressive conditions.  
 ICD-9-CM code(s) ICD-10-CM code(s) 
Comorbiditiesa   
History of MI 412 I25.2 
Congestive heart failure 428.0 – 428.9 I50.1 – I50.9 
Cerebrovascular disease 438.0 – 438.9 I69.00 – I69.998 
Dementia 290.0 – 290.9 F01.5 – F03.91 
Chronic pulmonary disease 490 – 496, 500 – 505, 506.4 
J40 – J47.9, J60 – J67.9, 
J68.4 
Rheumatic disease 
710.0, 710.1, 710.4, 714.0 – 
714.2, 714.81, 725 
M05.00 – M05.9, M06.00 – 
M06.9 
Peptic ulcer disease 
531.4 – 531.7, 532.4 – 532.7, 
533.4 – 533.7, 534.4 – 534.7 
K25.4 – K25.7, K26.4 – 
K26.7, K27.4 – K27.7, 
K28.4 – K28.7 
Mild liver disease 571.2, 571.4 – 571.6 
K70.30, K70.31, K74.0, 
K74.3, K74.4, K74.5, 
K74.60, K74.69 
Moderate or severe liver 
disease 
572.2 – 572.8 
K72.10, K72.90, K72.91, 
K76.6, K76.7 
Diabetes without chronic 
complications 
250.0 – 250.3, 250.7 
E10.10, E10.11, E10.61 – 
E10.69, E10.8, E10.9, 
E11.00, E11.01, E11.10, 
E11.11, E11.61 – E11.69, 
E11.8, E11.9, E12.00, 
E12.01, E12.10, E12.11, 
E12.61 – E12.69, E12.8, 
E12.9, E13.00, E13.01, 
E13.10, E13.11, E13.61 – 
E13.69, E13.8, E13.9, 
E14.00, E14.01, E14.10, 
E14.11, E14.61 – E14.69, 
E14.8, E14.9 
Diabetes with chronic 
complication 
250.4 –250.6 
E10.21 – E10.29, E10.31 – 
E10.39, E10.40 – E10.49, 
E10.51 – E10.59, E10.71 – 
E10.79, E11.21 – E11.29, 
E11.31 – E11.39, E11.40 – 
E11.49, E11.51 – E11.59, 
E11.71 – E11.79, E12.21 – 
E12.29, E12.31 – E12.39, 
E12.40 – E12.49, E12.51 – 
E12.59, E12.71 – E13.79, 
E13.21 – E13.29, E13.31 – 




E13.51 – E13.59, E13.71 – 
E13.79, E14.21 – E14.29, 
E14.31 – E14.39, E14.40 – 
E14.49, E14.51 – E14.59, 
E14.71 – E14.79 
Hemiplegia or paraplegia 342.0 – 342.9, 344.1 G81.0 – G82.54 
Renal disease 
582.0 – 582.9, 583.0 – 583.7, 
585.1 – 585.9, 586, 588.0 – 
588.9 
N03.0 – N03.9, N05.0 – 
N05.9, N18.1 – N18.9, 




HIV/AIDS 042, 079.53 B20 
Neutropenia 288.00 – 288.9 D70.0 – D70.9 
Organ transplant 
996.80 – 996.99, V42.0 – 
V42.9 
T86.00 – T86.99, Z94.0 – 
Z94.9 
Hematological malignancy 200.0 – 208.92 C81. 00 – C96.9 
Solid malignancy 
140.0 – 199.2, 209.0 – 
209.79, 235.0 – 239.9 
C00.0 – C80.2, C7A, C7B, 
D37.01 – D49.9 
Rheumatologic/inflammatory 
condition 
135, 277.30 – 277.39, 340, 
341.0 – 341.9, 357.0 – 357.9, 
422.0 – 422.99, 446.0 – 
446.7, 495.9, 516.0 – 516.9, 
555.0 – 558.9, 695.4, 710.0 – 
712.99, 714.0 – 714.9, 720.0 
– 720.9 
D86.0 – D86.9, E10.40, 
E10.42, E11.40, E11.42, 
E12.40, E12.42, E13.40, 
E13.42, E14.40, E14.42, 
E85.0 – E85.9, G35, G36.0 
– G36.9, G61.0 – G65.2, 
I40.0 – I40.9, I41, J67.9, 
J84.01 – J84.09, K50.00 – 
K52.9, K55.0 – K55.9, 
L93.0, L93.2,  M00.00 – 
M00.9, M01.X0 0 M01.X9, 
M02.10 – M02.19, M02.30 
– M02.39, M04.1, M05.00 
– M05.9, M06.00 – M06.9, 
M08.00 – M08.99, 
M11.00 – M11.9, M12.00 – 
M12.09, M30.0 – M30.8, 
M32.0 – M34.9, M35.00 – 
M35.3, M35.8, M35.9, 
M45.0 – M46.1, M46.50 – 
M46.59, M46.80 – M46.99, 
M49.80 – M49.89 
Other immune conditions 
279.0 – 279.9, 288.0 – 288.2, 
288.50 – 279.59, 288.8, 
288.9, 288.00 – 288.9, 
289.83, 289.89, 289.9, 
795.71, 795.79 
D47.4, D71, D72.0, 
D72.810 – D72.819, 
D72.89, D72.9, D75.81, 
D75.89, D75.9, D80.0 – 





Cause of admission   
Trauma 800.0 – 959.9 
S00.00XA – T34.99XS, 
T79.0XXA – T79.9XXS 
Urologic diseaseb 590.0 – 599.9, 996.64, 997.5 
N10 – N13.9, N16, N20.0 – 
N22, N28.0 – N37, N39.0 – 
N39.9, N99.0 – N99.89, 
T83.510 – T83.598S 
R80.2 
Abbreviations; ICD-9-CM, International Classification of Diseases, 9th edition, Clinical 
modification; ICD-10-CM, International Classification of Diseases, 10th edition, Clinical 
modification; CCI, Charlson Comorbidity Index; MI, myocardial infarction: HIV/AIDS, 
human immunodeficiency virus/acquired immunodeficiency syndrome 
a Only codes which could be applied to the index hospitalization were used; e.g. history of MI  
(ICD-9-CM 412) was included, but acute MI (ICD-9-CM 410-410.92) was excluded 







Table 4.2. Generic medication names used to classify medications of interest. 
 Generic medication name(s) 
Antibiotics, systemic  
β-lactams Amoxicillin, Ampicillin, Benzathine penicillin, 
Dicloxacillin,  Nafcillin, Oxacillin, Penicillin G, Penicillin 
V,  Piperacillin 
Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefepime, 
Cefixime, Cefotetan, Cefoxatime, Cefoxitin, 
Cefpodoxime, Ceftriaxone, Ceftaroline, Ceftazidime, 
Cefuroxime, Cephalexin, Cepodoxime proxetil 
Aztreonam  
Ertapenem, Imipenem, Meropenem 
Avibactam, Clavulanic acid, Sulbactam  
Ampicillin/Sulbactam, Amoxicillin/Clavulanate, 
Ceftolozane/tazobactam, Piperacillin/Tazobactam 
Colistin (colistamethate sodium), Daptomycin, 
Ethambutol, Isoniazid, Polymyxin B, Pyrazinamide, 
Metronidazole  
Aminoglycosides Amikacin, Gentamicin,  Neomycin, Paromomycin, 
Tobramycin 
Chloramphenicol Chloramphenicol 
Glycopeptides Telavancin, Vancomycin 
Macrolides Azithromycin, Clarithromycin, Erythromycin,  
Fidaxomicin, Telithromycin 
Oxazolidinones Linezolid, Tedizolid  
Quinolones Ciprofloxacin,  Levofloxacin, Moxifloxacin, Ofloxacin 
Rifaximin Rifaximin 
Sulfonamides Sulfadiazine, Sulfamethoxazole, Trimethoprim  






General Etomidate, Ketamine, Midazolam, Propofol 
Local Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, 
Ropivacaine, Tetracaine 
Anticholinergics   
Antipsychotics/neuroleptics Amitriptyline, Aripiprazole, Chlorpromazine, Clozapine, 
Desipramine, Doxepin, Droperidol, Fluphenazine, 
Haloperidol, Imipramine, Lurasidone, Nortriptyline, 
Olanzapine, Paliperidone, Paroxetine, Perphenazine, 




Quetiapine, Risperidone, Thioridazine, Thiothixene, 
Trifluoperazine, Ziprasidone 
Other Amantadine, Atropine, Baclofen, Benztropine, 
Carisoprodol, Cetirizine, Chlorpheniramine, Colchicine, 
Cyclobenzaprine, Cyproheptadine, Dexchlorpheniramine, 
Dicyclomine, Digoxin, Diphenhydramine, Diphenoxylate, 
Darifenacin, Fesoterodine, Hydroxyzine, Hyoscyamine, 
Loperamide, Loratadine, Meclizine, Pseudoephedrine, 
Ranitidine, Scopolamine, Solifenacin, Tizanidine, 
Tolterodine, Trospium 
Benzodiazepines Alprazolam, Chlordiazepoxide, Clobazam, Clomipramine, 
Clonazepam, Clorazepate, Diazepam, Flurazepam, 
Lorazepam,  Midazolam, Oxazepam, Temazepam 
Opioids Buprenorphine, Codeine, Fentanyl, Hydromorphone, 
Meperidine, Methadone, Morphine, Nalbuphine, 
Oxycodone, Oxymorphone, Sufentanil, Tapentadol, 
Tramadol 




Chemotherapeutic agents  
(alkylating) 
Bendamustine hydrochloride, Busulfan, Carmustine,  
Cyclophosphamide, Darabazine, Ifosfamide, Melphalan, 
Thiotepa 
Chemotherapeutic agents  
(antibiotics) 
 Bleomycin sulfate, Dactinomycin, Daunorubicin, 
Doxorubicin, Epirubicin, Idarubicin 
Chemotherapeutic agents  
(antimetabolites) 
Capecitabine, Cladribine, Clofarabine, Cytarabine,  
Fludarabine, Fluorouracil, Gemcitabine, Mercaptopurine, 
Methotrexate, Pemetrexed, Pentostatin 
Chemotherapeutic agents  
(antimitotics) 
 Docetaxel, Paclitaxel, Vinblastine, Vincristine, 
Vinorelbine 
Chemotherapeutic agents  
(monoclonal antibodies) 
Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab,  
 Ofatumumab, Rituximab 
Chemotherapeutic agents 
(other) 
Aldesleukin,  Arsenic trioxide, Asparaginase, Azacitidine, 
Brentuximab vedotin, Bortezomib, Carboplatin, 
Carfilzomib, Cisplatin, Dasatinib, Decitabine, Erlotinib, 
Etoposide, Everolimus, Imatinib, Irinotecan, Lapatinib, 
Mitoxantrone, Nelarabine, Nilotinib, Oxaliplatin, 
Pazopanib, Pegaspargase,  Pralatrexate, Procarbazine, 
Romidepsin, Sorafenib, Sunitinib, Temozolomide, 
Temsirolimus,  Topotecan, Tretinoin, Vorinostat 
Immune-modulating agents Abatacept, Adalimumab, Alefacept, Anakinra,  
Azathioprine, Basiliximab, Belatacept, Belimumab, 
Certolizumab pegol, Cyclosporine, Daclizumab, 
Denosumab, Eculizumab, Efalizumab, Etanercept, 
Fingolimod, Glatiramer, Golimumab, Infliximab, 




Interferon alfacon-1, Interferon beta-1a, Interferon beta-
1b, Interferon gamma-1b, Leflunomide, Lenalidomide, 
Muromonab-CD3, Mycophenolate acid, Mycophenolate 
mofetil, Natalizumab, Palifermin, Palivizumab, 
Pomalidomide, Pegademase bovine, Peginterferon alfa-2a, 
Peginterferon alfa-2b,  Sirolimus, Tacrolimus,  
Tocilizumab, Ustekinumab 
Systemic corticosteroids Betamethasone, Budesonide, Dexamethasone, 





Table 4.3. Hospitalization characteristics.  
 2013 – 2014 2015 – 2017 
Total hospitalizations, n  62,853 100,533 
Unique patients, n  41,941 64,633 
Female, n (%) 35,360 (56) 55,985 (56) 
Age, median (IQR) 52 (34 – 66) 53 (35 – 66) 
Race, n (%)   
White 37,766 (62) 60,089 (62) 
Black 16,625 (27) 26,378 (27) 
Asian 752 (1) 1,411 (1) 
Hawaiian/Pacific Islander 31 (<1) 79 (<1) 
Native American 533 (1) 908 (1) 
Other race 5,159 (8) 8,166 (8) 
Missing 1,987 3,502 
Cause of admissiona, n (%)   
Circulatory disease 8,166 (13) 13,440 (14) 
Injury or poisoningb 8,429 (13) 12,934 (13) 
Childbirth/complications of pregnancy 7,938 (13) 12,408 (13) 
Digestive disease 5,982 (10) 10,367 (11) 
Neoplasms 6,094 (10) 9,882 (10) 
Psychological disorders 4,485 (7) 6,738 (7) 
Infectious/parasitic disease 3,651 (6) 5,789 (6) 
Respiratory disease 2,977 (5) 4,674 (5) 
Musculoskeletal disease 2,286 (4) 4,462 (5) 
Endocrine/metabolic disease 1,959 (3) 3,233 (3) 
Genitourinary disease 2,106 (3) 3,313 (3) 
Nervous system disease 1,679 (3) 2,756 (3) 
Skin disease 1,116 (2) 1,778 (2) 
Blood disease 994 (2) 1,575 (2) 
Other or ill-defined 4,862 (8) 4,972 (5) 
LOS, days, median (IQR) 5 (3 – 8) 5 (3 – 8) 
Abbreviations: IQR, interquartile range; LOS, length of stay 
a Classified using primary diagnosis on each hospitalization; 2,341 
hospitalizations (1%) were unable to be linked to their diagnosis codes 




Table 4.4. Risk factor prevalence and hazard ratios for ND-UTIs, among adults hospitalized for >2 days between 2015 – 2017. 
 Prevalence 
N (%) 
Crude  Adjusteda 
 HR (95% CI) p-value  HR (95% CI) p-value 
Female 49,500 (56) 1.71 (1.37, 2.14) <0.0001  1.94 (1.50, 2.50) <0.0001 
Age, years       
18-39 years old 28,007 (32) ref –  ref – 
40-49 years old 11,018 (12) 1.78 (1.15, 2.75) 0.009  1.60 (1.00, 2.54) 0.05 
50-59 years old 15,631 (18) 2.12 (1.43, 3.15) 0.0002  1.88 (1.21, 2.93) 0.005 
60-69 years old 16,400 (19) 2.13 (1.46, 3.10) <0.0001  1.70 (1.10, 2.63) 0.02 
≥70 years old 17,431 (20) 2.86 (1.98, 4.12) <0.0001  2.06 (1.33, 3.21) 0.001 
Comorbidities       
Prior MI 5,434 (6) 1.47 (1.03, 2.09) 0.03  1.44 (0.96, 2.17) 0.08 
Heart failure 12,538 (14) 0.90 (0.68, 1.20) 0.47  0.79 (0.56, 1.11) 0.18 
Cerebrovascular disease 1,923 (2) 0.85 (0.40, 1.80) 0.67  0.64 (0.28, 1.46) 0.29 
Dementia 2,376 (3) 1.37 (0.85, 2.19) 0.20  0.94 (0.55, 1.61) 0.83 
Pulmonary disease 18,047 (19) 1.06 (0.82, 1.37) 0.65  0.95 (0.72, 1.27) 0.74 
Rheumatoid arthritis 1,708 (2) 1.65 (0.91, 3.01) 0.10  1.17 (0.59, 2.31) 0.65 
Peptic ulcer disease 441 (1) 2.45 (1.17, 5.10) 0.02  2.25 (1.04, 4.86) 0.04 
Diabetes 20,821 (23) 1.13 (0.89, 1.44) 0.31  1.10 (0.83, 1.45) 0.52 
Liver disease 3,320 (4) 0.93 (0.57, 1.51) 0.76  1.04 (0.59, 1.85) 0.89 
Renal disease 13,120 (15) 0.88 (0.66, 1.17) 0.37  0.72 (0.52, 1.01) 0.06 
Paralysis 1,915 (2) 3.39 (2.40, 4.80) <0.0001  3.14 (2.10, 4.72) <0.0001 
Immunosuppression 35,810 (40) 1.37 (1.10, 1.71) 0.005  1.48 (1.15, 1.91) 0.002 
Body mass index       
Under/normal weight 24,535 (33) ref –  ref – 
Overweight 21,129 (29) 1.00 (0.77, 1.32) 0.98  1.03 (0.77, 1.38) 0.85 
Obese 27,677 (38) 0.90 (0.70, 1.17) 0.43  0.91 (0.67, 1.22) 0.52 
Trauma admission 9,683 (11) 1.21 (0.92, 1.58) 0.17  1.36 (1.02, 1.81) 0.04 
Intensive care unit stayb 15,767 (20) 1.20 (0.94, 1.54) 0.15  1.27 (0.90, 1.78) 0.17 
MEWS       







2 27,062 (39) 0.88 (0.66, 1.17) 0.38  0.98 (0.72, 1.32) 0.88 
3 12,380 (18) 1.00 (0.72, 1.38) 0.99  1.06 (0.76, 1.49) 0.72 
≥4 11,367 (16) 0.82 (0.59, 1.15) 0.25  0.90 (0.63, 1.28) 0.54 
Morse fall risk       
0 4,626 (6) ref –  ref – 
1-24 19,862 (25) 1.28 (0.57, 2.88) 0.55  1.02 (0.43, 2.42) 0.96 
25-45 33,833 (42) 1.99 (0.93, 4.26) 0.08  1.55 (0.67, 3.59) 0.30 
>45 21,595 (27) 2.73 (1.28, 5.84) 0.01  1.83 (0.78, 4.33) 0.17 
Urinary retentionb 5,918 (7) 1.29 (0.93, 1.79) 0.12  1.41 (0.96, 2.07) 0.08 
Inpatient medicationsb       
Anesthesia, local 23,820 (27) 0.71 (0.56, 0.89) 0.003  0.70 (0.53, 0.92) 0.01 
Anesthesia, general 5,278 (6) 0.92 (0.69, 1.22) 0.56  0.95 (0.66, 1.35) 0.75 
Antibiotics 51,841 (59) 0.45 (0.36, 0.56) <0.0001  0.32 (0.24, 0.43) <0.0001 
Anticholinergics, antipsychotics 22,960 (26) 0.88 (0.70, 1.10) 0.27  0.96 (0.75, 1.23) 0.76 
Anticholinergics, other 27,909 (32) 1.01 (0.81, 1.25) 0.95  0.68 (0.53, 0.87) 0.002 
Benzodiazepines 28,293 (32) 0.60 (0.48, 0.76) <0.0001  0.66 (0.51, 0.87) 0.002 
Opioids 59,813 (68) 1.23 (0.91, 1.66) 0.18  1.62 (1.10, 2.39) 0.01 
Total parenteral nutritionb 1,544 (2) 1.78 (1.26, 2.50) 0.001  1.99 (1.35, 2.94) 0.0006 
Catheterizationb       
Urinary catheter 24,424 (28) 1.23 (0.99, 1.53) 0.07  1.16 (0.88, 1.53) 0.30 
Suprapubic catheter 255 (<1) 2.73 (1.12, 6.64) 0.03  2.28 (0.88, 5.91) 0.09 
Nephrostomy tube 526 (1) 2.36 (1.06, 5.26) 0.03  2.02 (0.83, 4.93) 0.12 
Urologic procedureb 1,288 (1) 1.86 (1.03, 3.37) 0.04  1.44 (0.72, 2.89) 0.30 
Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference; MI, myocardial infarction; MEWS, 
Modified Early Warning System 
a Adjusted for all risk factors included in table above; correlation between repeat hospitalizations of the same 
patients were taken into account using a robust sandwich covariance matrix and inpatient mortality was treated 
as a competing risk using the Fine and Gray model; inverse-probability of missingness weights were used to 
account for missing data 








Figure 4.1. A) Quarterly rates of non-device associated urinary tract infections (ND-UTIs), per 
10,000 hospitalization days and B) Proportion of urinary tract infections (UTIs) that are device 







Figure 4.2. Stacked cumulative incidences of non-device (ND-UTI, gray) and catheter associated 








CHAPTER 5: INCIDENCE AND RISK FACTORS OF NON-DEVICE ASSOCIATED 




Pneumonia is the most common healthcare associated infection (HAI) in the United 
States, and accounts for almost 25% of all hospital infections.1,2 Healthcare associated 
pneumonia poses a substantial burden on the healthcare system, with a 14% mortality and 
estimated to cost over $3 billion per year.5,21 Historically 83% of healthcare associated 
pneumonia cases have been considered to be ventilator associated (VAP), which is why the U.S. 
Centers for Disease Control and Prevention have traditionally focused surveillance efforts on 
VAP.21,28  
Recent studies have reported dramatic decreases in VAP rates over the past 15 years9; 
however, the rate of non-device associated pneumonia (ND-pneumonia) has remained stagnant 
during this period and ND-pneumonia now accounts for the majority of nosocomial pneumonia 
in hospitals settings.2,7,13,15-17,66 Despite this growing body of literature on the burden and 
importance of ND-pneumonia in hospitals, little is known about the risk factors for infection and 
there are currently no evidence-based guidelines for ND-pneumonia prevention.38,67 Thus, the 
purpose of this study was to update current estimates of ND-pneumonia rates and their frequency 






Data sources and study population 
 Electronic medical records (EMR) from adults (≥18 years old) admitted to the University 
of North Carolina (UNC) Hospitals between January 1, 2013 and December 31, 2017 were 
obtained from the Carolina Data Warehouse for Health (CDW-H), a central repository for 
clinical and administrative data from the UNC Healthcare System. Prisoners were excluded from 
analysis. Patients were able to have multiple hospitalizations during the study period. HAIs were 
identified through the UNC Hospitals’ Epidemiology database, which included both device and 
non-device associated HAIs, captured through comprehensive, hospital-wide active surveillance, 
in accordance with the Centers for Disease Control and Prevention (CDC) case definitions and 
methodology.13,31 In July 2014, UNC Hospital Epidemiology began also capturing ventilator 
associated events, a new surveillance concept that CDC developed as an alternative to traditional 
VAP surveillance.68 The two databases were then deterministically linked using admission date, 
medical record numbers, and full name. This study was approved by the UNC Institutional 
Review Board.   
 
Incidence of ND-pneumonia 
 Quarterly incidence rates, per 10,000 hospitalization days, between 2013 and 2017 were 
calculated and Poisson regression was used to assess a potential change in ND-pneumonia rates 
over time. The proportion of pneumonia cases that were non-device related each year were also 
calculated. Cochran-Armitage trend tests (two-sided) were used to test the null hypothesis that 
the proportion of ND-pneumonia cases did not change between 2015 and 2017 (after new 




Risk Factors for ND-pneumonia 
Only hospitalizations between 2015 and 2017 with a length of stay (LOS) >2 days were 
included in risk factor analyses. Potential risk factors of interest included patient sex, age 
(categorized as 18-39 years old [reference], 40-49 years old, 50-59 years old, 60-69 years old, 
and ≥70 years old), comorbidities, body mass index (BMI, categorized as under/normal weight 
[<25, reference], overweight [25.0 – 29.9], and obese [≥30.0]), immunosuppression (including 
neutropenia), Modified Early Warning Score (MEWS), Morse Fall scale, inpatient medication 
usage- specifically anesthetics, antibiotics, antipsychotics, benzodiazepines, opioids, and acid-
suppressing medications-, total parenteral nutrition (TPN), chlorhexidine mouthwash, prior 
endotracheal ventilation, prior tracheostomy, intensive care unit (ICU) stay, and trauma 
admission.. 
Patient comorbidities were captured using the discharge diagnosis ICD-9-CM (January 
2015 – September 2015) and ICD-10-CM (October 2015 – December 2017) codes on each 
record. Deyo et al. (1992) and Quan et al. (2005) algorithms were adapted to identify  
components of the Charlson comorbidity index (CCI) score (Table 5.1).41,42 Diagnosis codes for 
incident events (e.g. acute myocardial infarction) were removed from all component 
definitions.41 Peripheral vascular disease (PVD) was also excluded due to low incidence (n=201) 
and both malignancy (solid tumor or metastatic disease) and human immunodeficiency viruses 
(HIV) were incorporated into the broader classification of immunocompromised. Additionally, 
chronic pulmonary diseases were broken into more discrete categories (bronchitis/emphysema, 
asthma, bronchiectasis, and other chronic obstructive pulmonary diseases [COPD]). 
Immunocompromised patients were identified using the Advisory Committee on 




on which persons cannot receive live-attenuated vaccinations.43  Diagnoses of 
immunosuppressive conditions- which included HIV, neutropenia, organ transplant, and 
malignancy-  were identified using discharge diagnosis codes; relevant ICD-9-CM codes were 
identified using the Greenberg et al. (2016)44 algorithm and ICD-10-CM codes were identified 
using Centers for Medicare & Medicaid Services (CMS) General Equivalence Mappings 
(GEMS) (Table 5.1). Patients receiving chemotherapeutic agents, corticosteroids, or immune-
modulating agents within the first 2 days of their hospitalization were identified using inpatient 
medications (Table 5.2). Neutropenia was identified using both diagnosis codes and laboratory 
blood test results within the first 2 hospitalization days (defined as ≥2 white blood cell [WBC] 
counts <500 cells/mm3). 
Severity of illness and frailty were measured using the MEWS45 and Morse Fall 
Scale47,48, respectively.  These metrics are both automatically calculated within the UNC 
Hospitals EMR. The MEWS uses vital signs- specifically systolic blood pressure, heart rate, 
respiratory rate, temperature, conscious level, and hourly urine output (for two hours)- to identify 
patients at risk for imminent deterioration. The Morse Fall Scale includes history of falling, 
number of secondary diagnoses, whether ambulatory aid is needed, intravenous therapy/heparin 
lock, gait, and mental status and is used to predict future falls in hospitalized patients. For each 
patient, the first MEWS and Morse Fall Scale score within the first 2 days of admission was 
captured and categorized using the clinically relevant cut points (MEWS: <1 [reference], 2, 3, 
≥4; Morse Fall Scale: 0 [reference], 1-24, 25-45, >45). A MEWS ≥4 and a Morse Fall Scale 
score >45 are both considered indicators of severe illness. 
ICU stay, inpatient medications, chlorohexidine mouthwash, TPN, and device use were 




remainder of the hospitalization. For example, once a patient received antibiotics on day 4, they 
were considered to be exposed from day 4 until discharge, and were classified as unexposed on 
days 1-3. All medications were identified using orders captured in the EMR and receipt was 
confirmed using the medication administration record (Table 5.2). 
Multivariable Cox proportional hazards regression was used to simultaneously estimate 
the association between each potential risk factor and the incidence of ND-pneumonia. 
Correlation between repeat hospitalizations of the same patients were taken into account by 
utilizing robust sandwich covariance matrix estimates as described by Lee et al. (1992) and both 
VAP and inpatient mortality were treated as competing risks using the Fine and Gray (1999) 
model.39,40 
Due to missing values of BMI (n=15,146, 17%), MEWS (n=18,761, 21%) Morse Fall 
Scale (n=8,571, 10%), and location/discharge disposition (n=8,482, 10%), inverse-probability of 
missing weights (IPMW) were calculated.51 Weights were estimated using multivariable logistic 
regression, which modeled the probability of being a complete case as a function of the year and 
season of admission, cause of admission, patient age, sex, Charlson score comorbidities 
(excluding HIV and cancer), immunosuppression, TPN, medication usage anytime during 
hospitalization (antibiotics, antipsychotics, local anesthetics, general anesthetics, 
benzodiazepines, opioids, alpha-2 agonists, non-steroidal anti-inflammatory drugs [NSAIDs], 
calcium channel blockers, statins, angiotensin converting enzyme [ACE] inhibitors, angiotensin 
II receptor blockers [ARBs], histamine-2 agonists, proton pump inhibitors), device use (urinary 
catheter, ventilator, central venous catheter, peripheral venous catheter), whether they underwent 
any surgery (CPT 10021 – 69990), and LOS, as well as interaction terms between admission 




splines.52 Because 99% of hospitalizations from January-March 2015 were missing MEWS (28% 
of all missing), all hospitalizations in this time period were excluded.  
Our statistical analysis strategy is consistent with the American Statistical Association’s 
statements on p-values.54,55 All statistical computations were performed using SAS 9.4 (SAS 
Inc., Cary, NC). 
 
5.3 RESULTS 
 From 2013-2017 there were 163,386 hospitalizations (97,485 unique patients) and 771 
cases of healthcare associated pneumonia (520 ND-pneumonia, 191 VAP) during 666 unique 
hospitalizations at UNC Hospitals. Of the 771 pneumonia cases, 768 (99.6%) were successfully 
linked to a hospitalization record. 87% (n=142,836) of hospitalizations were >2 days (median 5 
days, interquartile range [IQR] 3-8 days). Patient demographics and causes of admission are 
described in Table 5.3.  
Median time to diagnosis was 9 days for ND-pneumonia (IQR 5-19) and 11 days for 
VAP (IQR 6-21). Between 2013 and 2017, the rate of ND-pneumonia was stable, with 4.15 ND-
pneumonia cases per 10,000 hospitalization days in 2013 and 4.54 ND-pneumonia cases per 
10,000 hospitalization days in 2017, p=0.65 (Figure 5.1.A). In 2013-2014 (prior to the 
implementation of the CDC’s updated definition for VAP), over 80% of pneumonia cases were 
non-device associated. Between 2015 and 2017 (after CDC ventilator associated event definition 
was implemented), the proportion of non-device infections ranged from 64% to 74%, p=0.09 
(Figure 5.1.B). From 2015-2017, only 36% (n=107) of ND-pneumonia cases occurred on the 
ICU, 45% (n=137) occurred on a floor, and 18% on a stepdown unit (n=55) (25 events could not 




occurred on an ICU (n=140). The 30-day and 60-day cumulative incidence of ND-pneumonia 
was 19.7 and 41.7 infections per 10,000 patients, respectively (Figure 5.2). 
 There were 88,487 hospitalizations between 2015 and 2017 with a LOS>2 days included 
in the risk factor analysis. Median IPMW was 1.07 (IQR 1.03-1.24, range 1.00 – 21.38); only 27 
hospitalizations had a weight >10. After adjustment, male sex and older age were associated with 
increased incidence of ND-pneumonia, Table 5.4. Additional risk factors included diagnoses for 
bronchitis or emphysema (HR 2.07, 95% CI 1.40, 3.06), congestive heart failure (HR 1.48, 95% 
CI 1.07, 2.05), paralysis (HR 1.72, 95% CI 1.09, 2.73), and immunosuppression (HR 1.50, 95% 
CI 1.16, 1.95). Being in an ICU was also associated with increased ND-pneumonia (HR 1.49, 
95% CI 1.06, 2.09). Conversely, patients with dementia were at lower risk of infection (HR 0.41, 
95% CI 0.18, 0.95). Our study failed to detect a change in ND-pneumonia risk for the following 
variables: use of chlorhexidine mouthwash, TPN, all medications of interest, and prior 
ventilation variables.  For chlorhexidine mouthwash, for example, while the hypothesis test of 
“HR=1” was inconclusive,  the point- and interval- estimates (HR 0.90, 95% CI 0.54, 1.52)  
indicate that the data are compatible with hazard ratios as small as 0.54 and as large as 1.52 in 
the target population.55 
 
5.4 DISCUSSION 
 Between 2013 and 2017 the rate of ND-pneumonia cases remained constant in UNC 
Hospitals, and non-device infections continue to account for the majority of hospital associated 
pneumonia cases. Risk factors for ND-pneumonia included male sex, older age, ICU admission, 




To the best of our knowledge, this is the most comprehensive analysis of ND-pneumonia rates 
and risk factors in an acute care setting. 
 The incidence and proportion of ND-pneumonia cases in our study are similar to rates 
reported by other centers. Davis and Finley, for example, utilized state-mandated comprehensive 
surveillance data from Pennsylvania and found that 71% of cases of pneumonia between 2009 
and 2011 were non-device associated (5,597 ND-pneumonia, 2,299 VAP).15 In a 2014 
convenience sample of 21 hospitals across the US, the rate of ND-pneumonia ranged from 0.12 
to 2.28 cases per 1,000 patient days.17 Our findings are also consistent with a prior report from 
our institution. Between 2008 and 2012, the proportion of non-device associated pneumonias 
increased from roughly 40% to 60%, predominantly due a decrease in device associated 
infections without concomitant change in the incidence of non-device associated infections.7 
Older age, pulmonary disease, and ICU stays have been associated with increased risk of 
VAP69.  In our study, we found  that these same risk factors extend to ND-pneumonia as well, 
albeit with some nuances.  We noted increased risk in middle-aged adults (40-49 and 50-59 years 
old) were at higher risk compared to patients 18-39 years old, and only specific types of 
pulmonary disease (bronchitis and emphysema) were at increased risk (differences in ND-
pneumonia risk among patients with asthma, bronchiectasis, and ‘other’ COPD were not 
detected). We also found that paralysis was associated with increased incidence of ND-
pneumonia. Paralytic agents and coma/stupor have been associated with VAP69,70, suggesting 
that limited mobility may increase a patient’s risk. Patients with paralysis may also have other 
neurological issues, like impaired swallowed or decreased level of consciousness, that could also 
account for the increased pneumonia risk. Male sex, chronic pulmonary disease, and congestive 




older adults.71 Overall, these finding suggest that there are certain characteristics that may 
predispose some adults to pneumonia infections.  
Interestingly, our study failed to detect an association between acid-suppressing 
medication (i.e. histamine-2 agonists and proton pump inhibitors [PPIs]), although they have 
been associated with increased risk of VAP.69  However, the literature for VAP is mixed. 
Additionally, evidenced-based guidelines and awareness of potential adverse effects have 
narrowed indications for acid suppression therapies in the acute care setting and UNC Hospitals 
implemented changes to the clinical guidelines for stress ulcer prophylaxis prior to the study 
period. Similarly, antipsychotics have also been associated with aspiration pneumonia in both the 
hospital72 and community setting73 but in our study failed to detect association between 
antipsychotic use and ND-pneumonia as well. 
 There have been a few recent studies that have found the use of oral care prevented ND-
pneumonia in high-risk patients (e.g. neurologic injury patients, older adults).30,37,74 While we 
failed to detect an association between chlorhexidine mouthwash and ND-pneumonia rates, this 
discrepancy could be due to targeted use of oral care with chlorhexidine at UNC Hospitals. As 
opposed to the universal use in prior studies, only 8% of hospitalized patients included in this 
analysis received the treatment. It is possible that these individuals were selected to receive oral 
care with chlorhexidine specifically due to perceived higher risk for respiratory infections- 
(although indication for chlorhexidine could not be determined) which could explain our 
inconclusive finding. Chlorhexidine mouthwash has also been associated with increased 
inpatient mortality.75 Studies assessing the utility of chlorhexidine mouthwash and oral care with 
VAP are mixed and there are currently no recommendations on its use for device associated 




This study is not without limitations. First, this was a single center study and results may 
not generalize to other hospitals, particularly if the patient population is different. We also did 
not account for duration, dose, or underlying indications for medication use. Additionally, ICD-
9-CM and ICD-10-CM codes were used to identify comorbidities. Using these codes likely 
underestimates the prevalence of comorbidities, although we expect this misclassification to be 
non-differential and, if anything, bias results towards the null. Similarly, ND-pneumonia and 
VAP were captured using CDC definitions, some of which require laboratory confirmation, and 
patients who are treated for suspected pneumonia but are not cultured would be missed. Finally, 
although we had a large sample size, the incidence of ND-pneumonia and prevalence of some 
risk factors were low, resulting in low levels of precision of the estimators as indicated by the 
widths of the observed confidence intervals.  
 In conclusion, between 2013 and 2017, the incidence rate of ND-pneumonia was 
unchanged, and non-device infections represent the majority of healthcare associated pneumonia 
cases in our acute care hospital. Our study and similar findings by others suggest that hospital 
infection prevention programs should consider expanding the scope of surveillance and 
prevention programs to include non-ventilated patients. Male sex, older age, 
bronchitis/emphysema, congestive heart failure, paralysis, immunosuppression, and ICU stays 
were all associated with increased risk of ND-pneumonia. Future research should continue to 
look for modifiable risk factors and assess potential prevention strategies.   
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Table 5.1. Diagnosis codes used to identify comorbidities and immunosuppressive conditions.  
 ICD-9-CM code(s) ICD-10-CM code(s) 
Comorbiditiesa   
History of MI 412 I25.2 
Congestive heart failure 428.0 – 428.9 I50.1 – I50.9 
Cerebrovascular disease 438.0 – 438.9 I69.00 – I69.998 
Dementia 290.0 – 290.9 F01.5 – F03.91 
Rheumatic disease 
710.0, 710.1, 710.4, 714.0 – 
714.2, 714.81, 725 
M05.00 – M05.9, M06.00 – 
M06.9 
Peptic ulcer disease 
531.4 – 531.7, 532.4 – 532.7, 
533.4 – 533.7, 534.4 – 534.7 
K25.4 – K25.7, K26.4 – 
K26.7, K27.4 – K27.7, 
K28.4 – K28.7 
Mild liver disease 571.2, 571.4 – 571.6 
K70.30, K70.31, K74.0, 
K74.3, K74.4, K74.5, 
K74.60, K74.69 
Moderate or severe liver 
disease 
572.2 – 572.8 
K72.10, K72.90, K72.91, 
K76.6, K76.7 
Diabetes without chronic 
complications 
250.0 – 250.3, 250.7 
E10.10, E10.11, E10.61 – 
E10.69, E10.8, E10.9, 
E11.00, E11.01, E11.10, 
E11.11, E11.61 – E11.69, 
E11.8, E11.9, E12.00, 
E12.01, E12.10, E12.11, 
E12.61 – E12.69, E12.8, 
E12.9, E13.00, E13.01, 
E13.10, E13.11, E13.61 – 
E13.69, E13.8, E13.9, 
E14.00, E14.01, E14.10, 
E14.11, E14.61 – E14.69, 
E14.8, E14.9 
Diabetes with chronic 
complication 
250.4 –250.6 
E10.21 – E10.29, E10.31 – 
E10.39, E10.40 – E10.49, 
E10.51 – E10.59, E10.71 – 
E10.79, E11.21 – E11.29, 
E11.31 – E11.39, E11.40 – 
E11.49, E11.51 – E11.59, 
E11.71 – E11.79, E12.21 – 
E12.29, E12.31 – E12.39, 
E12.40 – E12.49, E12.51 – 
E12.59, E12.71 – E13.79, 
E13.21 – E13.29, E13.31 – 
E13.39, E13.40 – E13.49, 
E13.51 – E13.59, E13.71 – 
E13.79, E14.21 – E14.29, 




E14.49, E14.51 – E14.59, 
E14.71 – E14.79 
Hemiplegia or paraplegia 342.0 – 342.9, 344.1 G81.0 – G82.54 
Renal disease 
582.0 – 582.9, 583.0 – 583.7, 
585.1 – 585.9, 586, 588.0 – 
588.9 
N03.0 – N03.9, N05.0 – 
N05.9, N18.1 – N18.9, 





490, 491.0 – 491.9, 492.0, 
492.8 
J40 – J44.1 
Asthma 493.0 – 493.92 J45.20 – J45.998 
Bronchiectasis 494.0, 494.1 J47.0 – J47.9 




HIV/AIDS 042, 079.53 B20 
Neutropenia 288.00 – 288.9 D70.0 – D70.9 
Organ transplant 
996.80 – 996.99, V42.0 – 
V42.9 
T86.00 – T86.99, Z94.0 – 
Z94.9 
Hematological malignancy 200.0 – 208.92 C81. 00 – C96.9 
Solid malignancy 
140.0 – 199.2, 209.0 – 
209.79, 235.0 – 239.9 
C00.0 – C80.2, C7A, C7B, 
D37.01 – D49.9 
Rheumatologic/inflammatory 
condition 
135, 277.30 – 277.39, 340, 
341.0 – 341.9, 357.0 – 357.9, 
422.0 – 422.99, 446.0 – 
446.7, 495.9, 516.0 – 516.9, 
555.0 – 558.9, 695.4, 710.0 – 
712.99, 714.0 – 714.9, 720.0 
– 720.9 
D86.0 – D86.9, E10.40, 
E10.42, E11.40, E11.42, 
E12.40, E12.42, E13.40, 
E13.42, E14.40, E14.42, 
E85.0 – E85.9, G35, G36.0 
– G36.9, G61.0 – G65.2, 
I40.0 – I40.9, I41, J67.9, 
J84.01 – J84.09, K50.00 – 
K52.9, K55.0 – K55.9, 
L93.0, L93.2,  M00.00 – 
M00.9, M01.X0 0 M01.X9, 
M02.10 – M02.19, M02.30 
– M02.39, M04.1, M05.00 
– M05.9, M06.00 – M06.9, 
M08.00 – M08.99, 
M11.00 – M11.9, M12.00 – 
M12.09, M30.0 – M30.8, 
M32.0 – M34.9, M35.00 – 
M35.3, M35.8, M35.9, 
M45.0 – M46.1, M46.50 – 
M46.59, M46.80 – M46.99, 
M49.80 – M49.89 
Other immune conditions 
279.0 – 279.9, 288.0 – 288.2, 
288.50 – 279.59, 288.8, 
D47.4, D71, D72.0, 




288.9, 288.00 – 288.9, 
289.83, 289.89, 289.9, 
795.71, 795.79 
D72.89, D72.9, D75.81, 
D75.89, D75.9, D80.0 – 
D80.9, D89.2, R75, R76.0, 
R76.8, R76.9 
Trauma 800.0 – 959.9 
S00.00XA – T34.99XS, 
T79.0XXA – T79.9XXS 
Abbreviations; ICD-9-CM, International Classification of Diseases, 9th edition, Clinical 
modification; ICD-10-CM, International Classification of Diseases, 10th edition, Clinical 
modification; CCI, Charlson Comorbidity Index; MI, myocardial infarction: HIV/AIDS, 
human immunodeficiency virus/acquired immunodeficiency syndrome 
a Only codes which could be applied to the index hospitalization were used; e.g. history of MI 
(ICD-9-CM 412) was included, but acute MI (ICD-9-CM 410-410.92) was excluded 
b Chronic obstructive pulmonary disease (COPD) from Charlson Comorbidity Index was 






Table 5.2. Generic medication names used to classify medications of interest. 
 Generic medication name(s) 
Antibiotics, systemic  
β-lactams Amoxicillin, Ampicillin, Benzathine penicillin, 
Dicloxacillin,  Nafcillin, Oxacillin, Penicillin G, Penicillin 
V,  Piperacillin 
Cefaclor, Cefadroxil, Cefazolin, Cefdinir, Cefepime, 
Cefixime, Cefotetan, Cefoxatime, Cefoxitin, 
Cefpodoxime, Ceftriaxone, Ceftaroline, Ceftazidime, 
Cefuroxime, Cephalexin, Cepodoxime proxetil 
Aztreonam  
Ertapenem, Imipenem, Meropenem 
Avibactam, Clavulanic acid, Sulbactam  
Ampicillin/Sulbactam, Amoxicillin/Clavulanate, 
Ceftolozane/tazobactam, Piperacillin/Tazobactam 
Colistin (colistamethate sodium), Daptomycin, 
Ethambutol, Isoniazid, Polymyxin B, Pyrazinamide, 
Metronidazole  
Aminoglycosides Amikacin, Gentamicin,  Neomycin, Paromomycin, 
Tobramycin 
Chloramphenicol Chloramphenicol 
Glycopeptides Telavancin, Vancomycin 
Macrolides Azithromycin, Clarithromycin, Erythromycin,  
Fidaxomicin, Telithromycin 
Oxazolidinones Linezolid, Tedizolid  
Quinolones Ciprofloxacin,  Levofloxacin, Moxifloxacin, Ofloxacin 
Rifaximin Rifaximin 
Sulfonamides Sulfadiazine, Sulfamethoxazole, Trimethoprim  






General Etomidate, Ketamine, Midazolam, Propofol 
Local Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, 
Ropivacaine, Tetracaine 
Antipsychotics/neuroleptics Amitriptyline, Aripiprazole, Chlorpromazine, Clozapine, 
Desipramine, Doxepin, Droperidol, Fluphenazine, 
Haloperidol, Imipramine, Lurasidone, Nortriptyline, 
Olanzapine, Paliperidone, Paroxetine, Perphenazine, 
Prochlorperazine, Promazine, Promethazine, Protriptyline,  





Benzodiazepines Alprazolam, Chlordiazepoxide, Clobazam, Clomipramine, 
Clonazepam, Clorazepate, Diazepam, Flurazepam, 
Lorazepam,  Midazolam, Oxazepam, Temazepam 
Histamine 2-agonists Cimetidine, Famotidine, Ranitidine 
Proton pump inhibitors Dexlansoprazole, Esomeprazole, Lansoprazole, 
Omeprazole, Pantoprazole 
Opioids Buprenorphine, Codeine, Fentanyl, Hydromorphone, 
Meperidine, Methadone, Morphine, Nalbuphine, 





Chemotherapeutic agents  
(alkylating) 
Bendamustine hydrochloride, Busulfan, Carmustine,  
Cyclophosphamide, Darabazine, Ifosfamide, Melphalan, 
Thiotepa 
Chemotherapeutic agents  
(antibiotics) 
 Bleomycin sulfate, Dactinomycin, Daunorubicin, 
Doxorubicin, Epirubicin, Idarubicin 
Chemotherapeutic agents  
(antimetabolites) 
Capecitabine, Cladribine, Clofarabine, Cytarabine,  
Fludarabine, Fluorouracil, Gemcitabine, Mercaptopurine, 
Methotrexate, Pemetrexed, Pentostatin 
Chemotherapeutic agents  
(antimitotics) 
 Docetaxel, Paclitaxel, Vinblastine, Vincristine, 
Vinorelbine 
Chemotherapeutic agents  
(monoclonal antibodies) 
Alemtuzumab, Bevacizumab, Cetuximab, Gemtuzumab,  
 Ofatumumab, Rituximab 
Chemotherapeutic agents 
(other) 
Aldesleukin,  Arsenic trioxide, Asparaginase, Azacitidine, 
Brentuximab vedotin, Bortezomib, Carboplatin, 
Carfilzomib, Cisplatin, Dasatinib, Decitabine, Erlotinib, 
Etoposide, Everolimus, Imatinib, Irinotecan, Lapatinib, 
Mitoxantrone, Nelarabine, Nilotinib, Oxaliplatin, 
Pazopanib, Pegaspargase,  Pralatrexate, Procarbazine, 
Romidepsin, Sorafenib, Sunitinib, Temozolomide, 
Temsirolimus,  Topotecan, Tretinoin, Vorinostat 
Immune-modulating agents Abatacept, Adalimumab, Alefacept, Anakinra,  
Azathioprine, Basiliximab, Belatacept, Belimumab, 
Certolizumab pegol, Cyclosporine, Daclizumab, 
Denosumab, Eculizumab, Efalizumab, Etanercept, 
Fingolimod, Glatiramer, Golimumab, Infliximab, 
Interferon alfa-2a, Interferon alfa-2b, Interferon alfa-n3, 
Interferon alfacon-1, Interferon beta-1a, Interferon beta-
1b, Interferon gamma-1b, Leflunomide, Lenalidomide, 
Muromonab-CD3, Mycophenolate acid, Mycophenolate 
mofetil, Natalizumab, Palifermin, Palivizumab, 
Pomalidomide, Pegademase bovine, Peginterferon alfa-2a, 





Systemic corticosteroids Betamethasone, Budesonide, Dexamethasone, 
Methylprednisolone, Prednisolone, Triamcinolone 
a Immunosuppressive medication use within the first 2 days of hospitalization were used to 






Table 5.3. Hospitalization characteristics. 
 2013 – 2014 2015 – 2017 
Total hospitalizations, n  62,853 100,533 
Unique patients, n  41,941 64,633 
Female, n (%) 35,360 (56) 55,985 (56) 
Age, median (IQR) 52 (34 – 66) 53 (35 – 66) 
Race, n (%)   
White 37,766 (62) 60,089 (62) 
Black 16,625 (27) 26,378 (27) 
Asian 752 (1) 1,411 (1) 
Hawaiian/Pacific Islander 31 (<1) 79 (<1) 
Native American 533 (1) 908 (1) 
Other race 5,159 (8) 8,166 (8) 
Missing 1,987 3,502 
Cause of admissiona, n (%)   
Circulatory disease 8,166 (13) 13,440 (14) 
Injury or poisoningb 8,429 (13) 12,934 (13) 
Childbirth/complications of pregnancy 7,938 (13) 12,408 (13) 
Digestive disease 5,982 (10) 10,367 (11) 
Neoplasms 6,094 (10) 9,882 (10) 
Psychological disorders 4,485 (7) 6,738 (7) 
Infectious/parasitic disease 3,651 (6) 5,789 (6) 
Respiratory disease 2,977 (5) 4,674 (5) 
Musculoskeletal disease 2,286 (4) 4,462 (5) 
Endocrine/metabolic disease 1,959 (3) 3,233 (3) 
Genitourinary disease 2,106 (3) 3,313 (3) 
Nervous system disease 1,679 (3) 2,756 (3) 
Skin disease 1,116 (2) 1,778 (2) 
Blood disease 994 (2) 1,575 (2) 
Other or ill-defined 4,862 (8) 4,972 (5) 
LOS, days, median (IQR) 5 (3 – 8) 5 (3 – 8) 
Abbreviations: IQR, interquartile range; LOS, length of stay 
a Classified using primary diagnosis on each hospitalization; 2,341 
hospitalizations (1%) were unable to be linked to their diagnosis codes 





Table 5.4. Prevalence and effect of potential factors for ND-pneumonia, among adults hospitalized for >2 days between 2015 – 2017. 
 Prevalence 
N (%) 
Crude  Adjusteda 
 HR (95% CI) p-value  HR (95% CI) p-value 
Female 49,500 (56) 0.64 (0.50, 0.82) 0.0003  0.77 (0.59, 1.00) 0.05 
Age, years       
18-39 years old 28,007 (32) ref –  ref – 
40-49 years old 11,018 (12) 2.41 (1.43, 4.08) 0.001  2.26 (1.28, 3.99) 0.005 
50-59 years old 15,631 (18) 3.24 (2.05, 5.12) <0.0001  2.58 (1.53, 4.36) 0.004 
60-69 years old 16,400 (19) 3.92 (2.52, 6.12) <0.0001  2.97 (1.78, 4.97) <0.0001 
≥70 years old 17,431 (20) 3.75 (2.39, 5.88) <0.0001  2.57 (1.49, 4.49) 0.0007 
Chronic pulmonary disease       
Bronchitis/emphysema 3,077 (4) 2.98 (2.14, 4.17) <0.0001  2.07 (1.40, 3.06) 0.0003 
Asthma 8,572 (10) 0.95 (0.63, 1.42) 0.79  1.17 (0.75, 1.81) 0.49 
Bronchiectasis 1,121 (1) 0.33 (0.08, 1.31) 0.11  0.54 (0.14, 2.16) 0.38 
Other COPD 6,923 (8) 1.14 (0.78, 1.67) 0.49  0.85 (0.56, 1.31) 0.47 
Other comorbidities       
Prior MI 5,434 (6) 1.34 (0.90, 1.99) 0.15  0.91 (0.58, 1.41) 0.66 
Heart failure 12,538 (14) 1.71 (1.32, 2.21) <0.0001  1.48 (1.07, 2.05) 0.02 
Cerebrovascular disease 1,923 (2) 1.29 (0.66, 2.51) 0.55  0.89 (0.41, 1.93) 0.77 
Dementia 2,376 (3) 0.47 (0.21, 1.06) 0.07  0.41 (0.18, 0.95) 0.04 
Rheumatoid arthritis 1,708 (2) 0.68 (0.26, 1.80) 0.44  0.52 (0.20, 1.38) 0.19 
Peptic ulcer disease 441 (1) 1.21 (0.38, 3.82) 0.75  0.93 (0.28, 3.04) 0.90 
Diabetes 20,821 (23) 1.06 (0.82, 1.37) 0.65  0.83 (0.61, 1.13) 0.24 
Liver disease 3,320 (4) 1.96 (1.32, 2.89) 0.0008  1.49 (0.95, 2.33) 0.08 
Renal disease 13,120 (15) 1.26 (0.96, 1.65) 0.09  0.94 (0.69, 1.28) 0.68 
Paralysis 1,915 (2) 2.12 (1.39, 3.24) 0.0005  1.72 (1.09, 2.73) 0.02 
Immunosuppression 35,810 (40) 1.51 (1.19, 1.91) 0.0007  1.50 (1.16, 1.95) 0.002 
Body mass index       
Under/normal weight 24,535 (33) ref –  ref – 
Overweight 21,129 (29) 0.83 (0.62, 1.09) 0.18  1.33 (0.98, 1.82) 0.07 
Obese 27,677 (38) 0.63 (0.48, 0.84) 0.002  0.80 (0.57, 1.14) 0.22 







Intensive care unit stayb 15,767 (20) 1.98 (1.53, 2.55) <0.0001  1.49 (1.06, 2.09) 0.02 
MEWS       
0-1 18,917 (27) ref –  ref – 
2 27,062 (39) 0.95 (0.69, 1.32) 0.77  1.07 (0.76, 1.49) 0.71 
3 12,380 (18) 0.94 (0.65, 1.37) 0.74  0.95 (0.64, 1.40) 0.78 
≥4 11,367 (16) 1.14 (0.82, 1.60) 0.44  1.07 (0.76, 1.52) 0.69 
Morse fall risk       
0 4,626 (6) ref –  ref – 
1-24 19,862 (25) 0.91 (0.37, 2.24) 0.84  0.79 (0.32, 1.92) 0.60 
25-45 33,833 (42) 1.87 (0.83, 4.24) 0.13  1.02 (0.44, 2.38) 0.95 
>45 21,595 (27) 2.93 (1.30, 6.63) 0.01  1.59 (0.68, 3.71) 0.28 
Inpatient medicationsb       
Anesthesia, local 23,820 (27) 1.06 (0.84, 1.34) 0.63  0.92 (0.69, 1.22) 0.54 
Anesthesia, general 5,278 (6) 1.57 (1.21, 2.05) 0.0008  1.12 (0.68, 1.83) 0.66 
Antibiotics 51,841 (59) 1.45 (1.06, 1.97) 0.02  1.15 (0.76, 1.74) 0.52 
Antipsychotics 22,960 (26) 0.87 (0.69, 1.10) 0.25  1.03 (0.80, 1.33) 0.83 
Benzodiazepines 28,293 (32) 0.94 (0.73, 1.21) 0.64  0.79 (0.58, 1.07) 0.13 
H2 blockers 15,833 (18) 1.29 (1.02, 1.65) 0.04  0.97 (0.71, 1.31) 0.82 
Proton-pump inhibitors 27,510 (31) 1.48 (1.18, 1.87) 0.0009  1.16 (0.90, 1.50) 0.25 
Opioids 59,813 (68) 1.69 (1.17, 2.45) 0.005  1.27 (0.78, 2.06) 0.34 
Total parenteral nutritionb 1,544 (2) 1.56 (1.09, 2.24) 0.02  1.37 (0.91, 2.08) 0.14 
Prior ventilationb       
Endotracheal 13,939 (16) 1.42 (1.11, 1.82) 0.005  1.10 (0.78, 1.55) 0.59 
Tracheostomy 4,348 (5) 1.05 (0.75, 1.47) 0.76  0.89 (0.61, 1.29) 0.53 
Chlorhexidine mouthwashb 6,362 (7) 1.53 (1.18, 1.98) 0.001  0.90 (0.54, 1.52) 0.70 
Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference; MI, myocardial infarction; MEWS, 
Modified Early Warning System; H2 blockers, histamine-type 2 receptor blockers 
a Adjusted for all risk factors in the table above; correlation between repeat hospitalizations of the same 
patients were taken into account using a robust sandwich covariance matrix and inpatient mortality was 
treated as a competing risk using the Fine and Gray model; inverse-probability of missingness weights were 
used to account for missing data 








Figure 5.1. A) Quarterly rates of non-device associated pneumonia (ND-pneumonia), per 10,000 
hospitalization days and B) Proportion of healthcare associated pneumonia that are device and 






Figure 5.2. Stacked cumulative incidences of non-device (ND-pneumonia, gray) and ventilator 








CHAPTER 6: DISCUSSION 
 
 
6.1 SUMMARY OF FINDINGS 
 The primary objective of the first aim was to describe the epidemiology of ND-UTIs, 
ND-pneumonia, and ND-BSIs, specifically, the rate of each infection, the relative frequency 
relative to device associated HAIs, and temporal trends in both. We found that between 2013 and 
2017, the rates of ND-UTIs and ND-pneumonia have remained relatively stable, and the rate of 
ND-BSIs has increased. Additionally, ND-UTIs and ND-pneumonia cases represent the majority 
of infections, with almost 3 in 4 UTIs and pneumonia cases being non-device associated in 2017. 
One in three BSIs are non-device associated at UNC Hospitals.  
 The primary objective of the second aim was to identify modifiable and non-modifiable 
risk factors associated with ND-HAIs. Females, older adults, peptic ulcer disease, paralysis, 
immunosuppression, opioid use, TPN, and trauma patients all had a higher risk of ND-UTI. 
Urinary retention, suprapubic catheters and nephrostomy tubes may also increase patient risk of 
ND-UTI, although estimates were imprecise. Risk factors for ND-pneumonia included male sex, 
older age, ICU admission, and chronic bronchitis/emphysema, congestive heart failure, paralysis, 
and immunosuppression. Risk factors for ND-BSIs included male sex, peptic ulcer disease, 
paralysis, general anesthesia, opioids, and peripheral venous catheters; higher Morse Fall Risk 
score, beta-blockers, and UTIs (device or non-device associated) also appeared to increase 





6.2 PUBLIC HEALTH IMPLICATIONS 
Incidence on ND-HAIs 
  Little is currently known about ND-HAIs and the majority of hospitals do not capture 
non-device infections as part of their surveillance practices. However, we found that the majority 
of UTIs and pneumonia cases are no longer device associated, and a substantial portion of BSIs 
are also non-device associated. These findings suggest that current targeted surveillance practices 
directed at patients with urinary catheters, on ventilators, and with central venous catheters alone 
are no longer sufficient to capture HAIs in acute care settings. This study is the most recent 
assessment of ND-HAIs and provides additional evidence that current targeted surveillance 
practices for HAIs needs to be updated to include ND-HAIs and evidence-based prevention 
strategies for these infections need to be developed and implemented in the United States. 
 
Risk Factors for ND-UTIs 
We found that patient demographics and comorbidities, specifically female sex, older 
age, peptic ulcer disease, paralysis, and immunosuppression, were associated with increased ND-
UTI incidence. Female sex, older age, paraplegia, and immunosuppression have also been shown 
to increase the risk for CA-UTIs, indicating that certain subsets of patients may be at higher risk 
for all UTIs.57-59 However, a recent study of CA-UTI found that after accounting for 
comorbidities and other severity measures age was no longer a predictor of infection, which 
likely means that age is a proxy for illness severity or frailty, and not an independent risk factor 
itself59. To the best of our knowledge, peptic ulcer disease has not been reported to be a risk 




retention, particularly in new users, females, and those ≥60 years old.60,61 However, peptic ulcer 
disease was associated with ND-UTI incidence even after adjusting for urinary retention, 
indicating that other factors may also be at play. 
 Inpatient medication use was also associated with ND-UTI incidence.  Patients receiving 
antibiotics, local anesthetics, anticholinergics, and benzodiazepines were at reduced risk for 
infection, and patients receiving TPN and opioids were at increased risk. Opioids have also been 
found to cause drug-induced urinary retention60, although opioid use may also be a proxy for 
acute pain and limited mobility (particularly after surgery), which may increase risk for UTIs, 
particularly in older adults62. Several studies have also found that TPN was associated with 
increased fungal infections, including UTIs, in hospitalized patients.63,64 Interestingly, we found 
that antibiotic use was associated with reduced incidence of ND-UTIs although antibiotic 
prophylaxis has not been found to reduce risk of CA-UTIs.8 And while local anesthetics, 
anticholinergics, and benzodiazepines are also known to cause urinary retention, anesthetics and 
benzodiazepines were associated with reduced risk of ND-UTIs, even in unadjusted analyses. It 
is possible that patients receiving these medications may represent an overall healthier patient 
population.  
 Finally, both suprapubic catheters and nephrostomy tubes were associated with increased 
incidence of ND-UTIs, but estimates were imprecise. A recent Cochrane review (2015) found 
that there was little or no difference in symptomatic UTI risk between short-term suprapubic 
versus indwelling catheters, but that patients with suprapubic catheters were catheterized for 
longer durations, which could explain the higher cumulative infection risk in this population.65 




definition, and the CDC has no recommendations for preventing CA-UTI in these populations, 
although they do call for further research on the topic.8 
 
Risk Factors for ND-pneumonia 
Older age, pulmonary disease, and ICU stays have been associated with increased risk of 
VAP69.  In our study, we found  that these same risk factors extend to ND-pneumonia as well, 
albeit with some nuances.  We noted increased risk in middle-aged adults (40-49 and 50-59 years 
old) were at higher risk compared to patients 18-39 years old, and only specific types of 
pulmonary disease (bronchitis and emphysema) were at increased risk (differences in ND-
pneumonia risk among patients with asthma, bronchiectasis, and ‘other’ COPD were not 
detected). We also found that paralysis was associated with increased incidence of ND-
pneumonia. Paralytic agents and coma/stupor have been associated with VAP69,70, suggesting 
that limited mobility may increase a patient’s risk. Patients with paralysis may also have other 
neurological issues, like impaired swallowed or decreased level of consciousness, that could also 
account for the increased pneumonia risk. Male sex, chronic pulmonary disease, and congestive 
heart failure have also been shown to increase the risk of community-acquired pneumonia in 
older adults.71 Overall, these finding suggest that there are certain characteristics that may 
predispose some adults to pneumonia infections.  
Interestingly, our study failed to detect an association between acid-suppressing 
medication (i.e. histamine-2 agonists and proton pump inhibitors [PPIs]), although they have 
been associated with increased risk of VAP.69  However, the literature for VAP is mixed. 
Additionally, evidenced-based guidelines and awareness of potential adverse effects have 




implemented changes to the clinical guidelines for stress ulcer prophylaxis prior to the study 
period. Similarly, antipsychotics have also been associated with aspiration pneumonia in both the 
hospital72 and community setting73 but in our study failed to detect association between 
antipsychotic use and ND-pneumonia as well. 
 
6.3 FUTURE RESEARCH 
Future studies should attempt to develop prevention strategies that target these potential 
risk factors, as well as replicate the current results. For example, targeting opioid use, and other 
urinary devices may be potential avenues to reduce the rates of ND-UTIs. As mentioned above, a 
recent review found that there was little or no difference in symptomatic UTI risk between short-
term suprapubic versus indwelling catheters65, but there are currently no CDC guidelines for 
either suprapubic catheters or nephrostomy tubes.8 And while we did find that antibiotics 
reduced the risk of ND-UTIs in our cohort, future research should assess whether prophylactic is 
a viable strategy, especially since it is not currently recommended for CA-UTI prevention.8 
There have been a few recent studies that have found the use of oral care prevented ND-
pneumonia in high-risk patients (e.g. neurologic injury patients, older adults).30,37,74 While we 
failed to detect an association between chlorhexidine mouthwash and ND-pneumonia rates, this 
discrepancy could be due to targeted use of oral care with chlorhexidine at UNC Hospitals. As 
opposed to the universal use in prior studies, only 8% of hospitalized patients included in this 
analysis received the treatment. It is possible that these individuals were selected to receive oral 
care with chlorhexidine specifically due to perceived higher risk for respiratory infections- 
(although indication for chlorhexidine could not be determined) which could explain our 




inpatient mortality.75 Studies assessing the utility of chlorhexidine mouthwash and oral care with 
VAP are mixed9, and future research is needed to provide additional evidence on whether  
chlorhexidine mouthwash is a viable prevention strategy for healthcare associated pneumonia. 
 
6.4 CONCLUSIONS 
 ND-HAIs represent a substantial proportion of all HAIs, and rates of these infections 
have remained relatively unchanged over the past decade. This study, and similar findings by 
others suggest that hospital infection prevention programs should consider expanding the scope 
of surveillance and prevention programs to include ND-HAIs. Additionally, we identified several 
modifiable and non-modifiable risk factors for ND-UTIs and ND-pneumonia, including patient 
sex, age, comorbidities, opioid use, suprapubic catheters and nephrostomy tubes. Future research 
should continue to identify risk factors for ND-HAIs and develop potential prevention strategies 
for these infections.   
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